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ABSTRACT

ON THE RELATIONSHIP OF DIABETES AND SLEEP APNEA:
EVOLUTION AND EPIGENETICS

Nancy Wilson
Department of Microbiology and Molecular Biology
Bachelor of Science Honors
This thesis gives an overview of the relationship between diabetes, sleep apnea,
obesity, and heart disease. It then addresses evidence that the traditional understanding of
this relationship is incomplete or misleading. In the process, there is a brief discussion
of the evolutionary rationale for the development and retention of sleep apnea in light
of blood sugar dysregulation, as an adaptive mechanism in response to environmental
stressors, followed by a brief overview of the general concepts of epigenetics. Finally,
this paper presents the results of a literature search on the epigenetic marks and changes
in gene expression found in sleep apnea and diabetes. (While some of these marks will
also correlate with obesity and heart disease, that is beyond the scope of this project.)
This thesis concludes with an exploration of alternative explanations for the etiology of
these interlinking diseases.
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Importance
Diabetes is the seventh leading cause of death in the United States today,1 with type II
diabetes representing over 90% of all diabetes cases.2 Of the top ten causes of death in the
United States over the last decade, diabetes has been known to exacerbate or trigger all
of the others3. Between thirty4 and eighty5 percent of diabetics (including type I diabetics)
also have sleep apnea; sleep apnea has been shown to be independently associated with
insulin resistance,6 with the severity of sleep apnea corresponding with the severity of
insulin resistance.7 Sleep apnea is even associated with gestational diabetes.8 While both
sleep apnea and diabetes are believed to spring from obesity, the two conditions occur
together more often than can be explained by obesity alone.9

Purpose
The purpose of this paper is to improve our understanding of the relationship between
sleep apnea and diabetes. This will be done by exploring the evolutionary background
of these diseases and by examining epigenetic marks common to both conditions.10 This
should give a clearer picture of the underlying etiology of these diseases and point to
1 Global pandemic aside. See: CDC (n.d. “Leading Causes of Death”) and JAMA Network (2021).
2 Reutrakul and Mokhlesi 2017, 1070-86
3 While this claim may at first appear worthy of skepticism, the careful reader will note that it is, in fact,
perfectly accurate.
4 Papanas et al. 2009, 751-56
5 Aronsohn et al. 2010, 507-13
6 While insulin resistance is widely regarded as a major precursor for type II diabetes, type I diabetics
can also experience insulin resistance. For purposes of this paper, I will be specific where my sources allow
me to, but I may at times use the terms “diabetes,” “type II diabetes,” “metabolic syndrome,” and “insulin
resistance” somewhat interchangeably.
7 Ip et al. 2002, 670-76; also Araújo et al. 2015, 1351-57
8 Facco et al. 2014, 559.e1–559.e6
9 Muraki, Hiroo, and Tanigawa 2018, 991-97.
10 Evo-Devo (evolutionary developmental biology) teaches us that evolutionarily successful changes
usually target regulatory processes more than underlying DNA sequences. The science of epigenetics is the
study of regulatory signaling of the genome. This is why I am looking at epigenetic marks. For an enjoyable,
scientifically accurate overview of evo-devo, I recommend A Capella Science’s “Evo-Devo (Despacito Biology Parody)” (2017).
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productive future avenues of research in the search for cures to these major health issues.
Overview
What are sleep apnea and diabetes? What causes them, and what are the results of
these diseases?
Sleep apnea is a condition in which breathing stops during sleep, either because
the brain is not correctly signaling the body to breathe (central sleep apnea, or CSA)
or because soft tissues, primarily the tongue, collapse across the airway, obstructing
it (obstructive sleep apnea, or OSA).11 Sleep apnea is associated with inflammation,12
metabolic syndrome and diabetes mellitus,13 obesity,14 heart disease,15 stroke,16 and death.17
Diabetes, on the other hand, is a condition characterized by hyperglycemia. Type
I Diabetes is generally regarded as an autoimmune disorder brought on by the body’s
attack on the insulin producing cells of the pancreas. Type II Diabetes is generally
regarded as a progressive disease, with metabolic syndrome and insulin resistance giving
way to full-blown type II Diabetes, characterized by insufficient insulin production.
Diabetes is associated with heart disease, some cancers, stroke, respiratory sensitivity,
blurred thinking and dementia, kidney disease, nerve damage, blindness, depression,
and death. Together, sleep apnea, diabetes, and cardiovascular disease make up a large
proportion of the diseases of modern life.18

11 Lochan 2011, 7-14
12 Araújo et al. 2015, 1351-57
13 Dobrota et al. 2021, 76-84
14 Kapur 2010, 1155-67
15 Araújo et al. 2015, 1351-57
16 NHLBI 2010
17 Yaggi et al. 2005, 2034-41.
18 While we do not address causes of autoimmunity here, it should be noted that type I Diabetes, along
with allergies, arthritis, and other autoimmune disorders, is increasing alongside more obvious diseases
of modern lifestyles, such as type II Diabetes. See National Diabetes statistics report, found at CDC (2020,
“National Diabetes Statistics Report”).
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A well-known solution

A naive model of lifestyle diseases
Metabolic
syndrome &
diabetes
Obesity

Exercise
Calories

Sleep
apnea

Other
lifestyle
diseases

Figure 1 Neat, plausible, and wrong. This naive model posits obesity as the
lynchpin of lifestyle disease. If obesity is the lynchpin, weight loss is the selfevident treatment and cure. Unfortunately, this model doesn’t fit the data we have.

Widely held views of these diseases of modern life can be strung into a sort of
narrative, which goes something like this:
“Once upon a time, humans had to work very hard all the time and were
always a little bit hungry. Fat and sugar were especially difficult to obtain,
so humans evolved to be very efficient at using fat and sugar and also to
constantly seek them out. Unfortunately, if we ingest very much fat or sugar
we become obese. This is because obesity is caused by eating too much and
exercising too little. Obesity itself is a disease state with no benefit to the
individual. Because of industrialization, fat, sugar, and calories in general
are now widely available for the first time in human history. Industrialization
also made life easier, so we don’t have to work so hard.19 The abundance of
calories with the lack of physical labor created a mismatch between calories
taken in and those expended: this mismatch is the underlying cause of diseases
of modern life, especially obesity, diabetes, and heart disease. Sedentary
individuals who indulge themselves by eating too many calories are the people
who get those diseases. In particular, obesity causes sleep apnea,20 diabetes,
19 For an otherwise well-written article which uses this chain of reasoning as the backdrop for the research, see, for example, Ling and Rönn 2019.
20 Kapur 2010 is a great example of how this reasoning works: establishing from well-structured studies
that sleep apnea is correlated with weight gain, and that increased severity of sleep apnea is correlated with
increased weight gain, the author goes on to casually state that the weight gain clearly caused the sleep apnea, though in the same paragraph he states that weight loss does not decrease severity of sleep apnea to the
same extent that weight gain increased it. Relevant here is the aphorism, “correlation is not causation.”
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and heart disease. To cure those diseases, we would have to change human
nature such that people would choose to eat less and exercise more. Those who
exert themselves to eat less and exercise more can cure themselves of these
diseases, including obesity.”

This is a tidy story which carries the appeal of placing responsibility for “lifestyle
disease” squarely on the individual experiencing it. It’s also appealing because it suggests
that we can avoid said diseases through practice of willpower — by denying ourselves
the pleasures of sugar and fat and forcing ourselves to exercise enough. This tale of
willpower-derived redemption from the diseases of modern life holds grave significance
for many of us.21 Unfortunately, it also has the possibility of living up to H.L. Mencken’s
dictum, “There is always a well-known solution to every human problem—neat,
plausible, and wrong.” Let us examine the elements of this story, then, and see how they
bear up to scrutiny.
Once upon a time, humans had to work very hard all the time and were always a
little bit hungry.
There is a great deal of evidence to suggest that our distant ancestors had periods
of prosperity, even to the point of allowing obesity.22 In addition, it has been suggested
that the agricultural revolution—in which humans undertook deliberate cultivation of
food rather than the nomadic, gatherer-hunter lifestyle they had previously lived—led
to various health issues such as anemia and loss of stature.23 This is hardly the response
of people who had previously been underfed. Possibly the strongest evidence that
our ancestors were not routinely deprived of calories, though, comes from the field of
21 According to the CDC, 1 in 10 Americans adults have diabetes, and 1 in 3 have prediabetes (CDC, n.d.
“National Diabetes Statistics Report, 2020”).
22 See, for example, depictions of the “Woman of Willendorf.”
23 See Latham 2013 or Mummert et al. 2011, 284-301.
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epigenetics. Many of the studies in this field focus on natural experiments, where humans
were starved due to external factors such as war or famine.24 Children and grandchildren
of those underfed individuals show a strong predisposition toward obesity and heart
disease, as well as diabetes and other metabolic problems. We do not yet know how many
generations of stable caloric intake are required to reverse these inherited metabolic
changes. The fact that the epigenome changed with exposure to starvation conditions tells
us that our ancestors had a non-starvation state available.
Fat and sugar were especially difficult to obtain, so humans evolved to be
very efficient at using fat and sugar, and also to constantly seek them out.
Unfortunately, if we ingest very much fat or sugar we become obese.
From 1990s weight-loss guru Susan Powter’s mantra, “Fat makes you fat” to decades
of FDA recommendations that Americans limit their refined sugar and fat consumption,
we’ve all heard the message that fat and sugar are the biggest culprits in causing obesity
and resultant diseases.
Nina Teicholtz addresses this in her groundbreaking book, The Big Fat Surprise
(2014). She looks at all of the studies on which recommendations of low-fat diets have
been made, and she presents the well-researched conclusion: We do not know what we
think we know. Fat in our diets has not been shown harmful to our health and may well
be helpful.25 Sugar is obliquely implicated in lifestyle diseases, but the data may not be
as clear as we have been led to believe. We don’t know what causes a human to tip over
from less than fit into downright unhealthy. Is there a dietary component? Both common
24 See, for example, Senaldi and Smith-Raska 2020.
25 Reading Teicholtz, one also comes to the realization that some of the first researchers nutritional
researchers defined the boundaries of what we study regarding fats and sugars, and those boundaries haven’t
been changed. We don’t know if some animal fats are better or safer than others (like butter vs lard) because
the boundary of study was drawn between animal and plant fats (butter and lard vs canola oil and olive oil).
The definitional boundaries having been drawn and unchallenged, all we can say for sure is that
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sense and research suggest that there is. But particular foods like red meat or fresh
cucumber have neither been exonerated nor incriminated as the source of our troubles.
Even the much-vaunted “Mediterranean diet” of popular fame has never been properly
defined26—and therefore, it has never been properly studied.
Happily, we do have evidence for a dietary explanation. A Brazilian nutrition
researcher named Monteiro and his team were puzzled at data that showed people in
Brazil were buying less sugar and less oil—but at the same time experiencing more
obesity and more diabetes. Eventually they reached the conclusion that the culprit was
what they have labeled UFPs, or “Ultra Processed Foods.”27 While this classification
has been opposed by some as “nonsensical,” it gained a great deal of traction when a
physicist from the U.S. named Kevin Hall set out to show it was the content, rather than
the processing, that was the problem. After some gold-standard pilot studies, Hall now
suggests avoiding ultra-processed foods.28
Obesity is caused by eating too much and exercising too little.
This assumption is actually based on a truism, namely, if you put more into a
system than goes out, the system must expand. It may expand gradually—as with
obesity—or explode—as with the case of an overfilled water balloon—but expand it
will. The problem with this particular application is that we, do not simply expand or
contract according to how much we are holding. As living, homeostatic systems, we
have numerous mechanisms for maintaining (among other things) our temperature, our
hydration levels, our electrolyte balance—and our weight.
26 Again, see Teicholtz 2014 for a thorough explanation.
27 Monteiro 2009, 729-31. For those who wish a well written summary with commentary, I recommend
Bee Wilson’s “How Ultra-processed Food Took Over Your Shopping Basket” (2020).
28 For more information about Hall’s work, see Shell (2019. 38-45).
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In fact, however large or small we are, our baseline metabolism accounts for the
largest proportion of calories we expend, regardless of our physiological overlay.29
Principles of biological homeostasis suggest that a healthy individual will not need to
regulate their intake to the exact calorie on a given day—rather, the metabolism changes
in mild ways to compensate for the inevitable caloric variability of diet.30 In addition,
unfortunate natural experiments like the Dutch “hunger winter”31 and alternating years of
prosperity and famine in record-keeping Scandinavian countries32 have given us the data
to understand that low-calorie maternal (P0) conditions impel offspring (F1, F2, F3) to
greater levels of many undesirable things: obesity, metabolic syndrome33, hypertension,
type II diabetes, and other health conditions.34 Modern data does not suggest that
improving the caloric intake of offspring will reduce obesity in themselves (F1) or their
offspring (F2, F3, etc.), either.35
Obesity is a disease state with no benefit to the individual.
As early as 1987, an entire issue of the Journal of Obesity and Weight Regulation was
devoted to Ernsberger and Haskew’s alternative theories of obesity, namely, that it is not
a disease state. They state clearly that obesity might result from a disease state—much as
pale skin or heightened stature may indicate disease states, but may also be a desirable
29 This is why exercise only slims a small part of the population: all of us benefit from exercise, but not all
of us are tipped out of our current homeostasis into a more slender form by exertion.
30 Or, as expressed by St-Pierre and Tremblay (2012, 292-97), “The ability of healthy individuals to maintain body weight in the face of fluctuating energy intake and expenditure is due to an intricate physiological
network that acts as the gatekeeper of energy balance. Indeed, under normal physiological conditions, any
deviation in energy intake or expenditure is compensated for by physiological and behavioral responses that
oppose these changes in order to return to a state of energy balance.”
31 Roseboom et al. 2001, 93-98.
32 A good overview can be found in Senaldi and Smith-Raska 2020.
33 Metabolic syndrome is defined by the World Health Organization as glucose intolerance and insulin
resistance, either separately or together, in combination with two or more of the following: hypertension;
elevated plasma triglycerides; reduced HDL cholesterol, central obesity, and microalbuminuria.
34 Painter et al. 2008, 1243-49.
35 Painter et al. 2008, 1243-49.
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result of genes, environment, or both. Just as none would suggest that the paleness
of anemia should be cured by sending the sufferer to attend a local tanning parlor,
Ernsberger and Haskew suggest that we may simply add to the problems of obesity if we
try to ”cure” it through the panacea of weight loss. Ernsberger and Haskew are not alone
in their theories. Indeed, there have been a number of articles published in the last few
years bemoaning the “obesity paradox,”36 as it has been called—namely, that individuals
who fall prey to diabetes or a number of other conditions live longer and have fewer
complications than those who are slimmer when diagnosed. Additionally, individuals
who are “normal weight” have lower death rates than those who are merely 20% under
“normal weight;” those who are above the “ideal weight” have lower death rates still.37
Evolutionary biology teaches us that conserved traits are generally important—and
beneficial—to the group, and by extension, to the individual. The ability to become obese
seems to be a conserved trait across species. As such, treating it as a disease state may be
misleading and even harmful. One explanation for the apparent paradox of obesity being
closely associated with disease states, yet also being associated with better outcomes in
those disease states, is that obesity could be protective against the true underlying causes
of those health issues. Much as doctors in time past strove to remove blood from the body
through leaches and bleeding, the practice of removing adipose tissue through diet and
surgery may not be providing the cures we seek.
Because of industrialization, fat, sugar, and calories in general are now widely
available for the first time in human history. Industrialization also made life
easier, so we don’t have to work so hard.
This is, in some ways, a reprise of the idea that humans are getting fatter because
36
37

See, for example, Artham et al. (2008, 24-41) or Beddhu (2004, 229-32).
Ernsberger and Haskew 1987
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we are failing to properly account for our water-balloon-like nature in a changing
environment. But humans aren’t the only animals getting fatter. Such disparate species
as wild marmosets and fully supervised lab rats have gotten bigger over the last few
decades.38 This suggests it is neither human character traits nor human diet and lifestyle
choices that are causing the changes in human population fatness,39 but some other factor,
be it light pollution40 or ultra-processed foods41 (are wild marmosets somehow indulging
in leftover Twinkies?) or old-fashioned air pollution42 or some other, unidentified cause.43
The abundance of calories with the lack of physical labor created a mismatch
between calories taken in and those expended: this mismatch is the underlying
cause of diseases of modern life, especially obesity, diabetes, and heart disease.
Correlation is not causation. While fatness is strongly associated with diseases of
modern life, it may be the proverbial “healthy response to an unhealthy situation”—
fatness may be protecting us from some of the worst effects of “lifestyle diseases.”
Sedentary individuals who indulge themselves by eating too many calories are the
people who get those diseases.
This view is contradicted by the fact that only half of obese people have metabolic
syndrome, while fully ten percent of the lean population has metabolic syndrome.44 It
38 Berreby 2013
39 Here I use the term “fatness” interchangeably with the term, ‘obesity,’ although I prefer the first, as
being more precise. As Ernsberger and Haskew (1987) point out, ‘obesity’ is defined by the mathematical
derivation of BMI, rather than actual body mass composition, whereas ‘fatness’ refers to the adipose composition of a body. In deference to general convention, however, we have usually used the term ‘obesity,’
here.
40 I do not have space here to explore the possibility of light pollution as a potential source of metabolic
disruption but suggest Król and John R Speakman (2007, 271-78) as a starting point. More broadly, on the
subject of diurnal regulation, I recommend Till Roenneberg’s excellent book, Internal Time (2012).
41 For a summary of the evidence regarding ultra-processed foods, see Wilson 2020.
42 See McConnell et al. (2016, 1-3) or Ahmed et al. (2018, 336).
43 In “Metabolic Implications of Body Fat Distribution” (1991, 1132-43), Bjorntorp correlates several
studies surrounding hormones, fat distribution, and insulin resistance. He declares, “this … suggests that
endocrine aberrations may be of more importance than visceral fat accumulation . . . for insulin resistance.”
44 This statistic is reported by Brown (2002, 774-78) from the work done by Mantzoros and Flier (1995,
193-232
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is, of course, important to get this right: If obesity is, after all, the trigger for metabolic
syndrome, with its concomitant heart disease and short path to diabetes, it would
be logical—perhaps imperative—to target fatness as the first link in the chain for
intervention. If it is not, however, the first link in this chain, changing an individual’s
body profile (from fatter to slimmer, for example) will at best do nothing to help their
long-term health prospects—it may even hurt them by interfering with an important
response to an environmental stimulus. Even if weight loss does no harm per se, it may
provide a false sense of progress against underlying disease, even while the underlying
disease is still at work.
In particular, obesity causes sleep apnea, diabetes, and heart disease.
In Mansor et al.’s (2016) research on why the hearts of diabetic patients often fail
to repair themselves at the same rate as those of nondiabetic patients, they describe a
metabolic shift that takes place when the cells of the heart need repair. Normally, hypoxic
events cause a shift in heart-cell metabolism toward a high-glucose energy use. Mansor et
al. discovered that this shift mechanism is still fully functional in a diabetic heart cell, but
because the underlying diabetes shifts the cellular metabolism to a primarily fatty-acidbased energy use, even a normally functioning hypoxia-induced cascade does not lead to
full glucose metabolism or normal cellular repair. Hypoxic events can be caused not only
by heart attacks or strokes but also by temporary changes in breathing; if those breathing
changes occur during sleep, they are classified as sleep-disordered breathing, or sleep
apnea.
The field of linguistics holds other clues to support this possibility. The advent
of fricatives in human speech corresponds with a softer diet, around the time of the
10

first agricultural revolution (Blasi et al. 2019, eaav3218). Blasi et al. point out that
softer foods can cause a difference in jaw development, leading to the modern human
overbite and allowing fricatives such as “f” and “v” to enter human speech. Soft foods,
such as grains (fermented and otherwise) and sweet fruit (more widely available when
planted than when stumbled upon), would have been much more available after the first
agricultural revolution than before. These soft foods are also much more likely to cause
hyperglycemia, the primary diagnostic factor in diabetes.
Richard Wrangham (2017, S303–13) makes a strong case that Homo habilis, Homo
erectus, and Homo neanderthalensis all probably cooked some of their food. That
corresponds with smaller jaws and teeth in Homo erectus than in earlier hominids. So
the final transition to having the ability to talk came with the final transition to being
dependent on cooking in the most recent hominids: Homo sapiens, also known as us.
Davidson et al. (2005) hypothesized that obstructive sleep apnea in humans is a
side-effect of our capacity for speech. To evaluate this hypothesis, the authors evaluated
men with sleep apnea for severity of sleep apnea and also measured several areas
between the face and pharynx/larynx corresponding to the human capacity for speech.
They found a strong correlation between some of these measurements (especially
cranial base angulation and laryngeal descent) and the severity of the subjects’ sleep
apnea; this correlation corroborates the theory that sleep apnea is a result of those same
changes that allow speech.
So we see that paleoarchaeological evidence in conjunction with modern research
allows for the coevolution of sleep apnea and hyperglycemia in response to a softer,
cooked diet, though of course it cannot prove any such thing. But there are further clues.
11

Evolutionary theory informs us that co-evolution indicates advantage to the
organism—not as individuals but as a species. Did our ancestors from 10,000 years ago
get fat in conjunction with snoring? Possibly.45
To cure those diseases, we would have to change human nature such that people
would choose to eat less and exercise more.
This, of course, is true insofar as the underlying assumptions are true, namely:
people get sick because they got fat, and they get fat because of personal choices to eat
too much and exercise too little. If, however, the diseases of modern life have a more
complex pathogenesis involving interactions between personal choices and a host of
environmental factors, it may be possible to stem the tide of lifestyle-based diseases
by changing the environment. Importantly, even if only a small part of lifestyle-based
diseases were caused by environmental factors, changing those factors could cure that
portion of lifestyle-based diseases.
Those who exert themselves to eat less and exercise more can cure themselves of
these diseases, including of obesity.
While there is much anecdotal evidence of long-term weight loss accompanied by
a return to full health, a preliminary survey of the literature on weight loss and exercise
interventions for treatment of diabetes revealed a very low long-term success rate.46 While
reduced calories and increased exercise appear to help ameliorate the health problems of
45 Anecdotal evidence suggests that we are much more likely to snore if sleeping alone or after physically demanding activities. This being the case, it has been postulated that snoring may serve as a last-ditch
protection against predators who would risk going up against a sole human but not against a roaring crowd
of humans—an impression some snorers do indeed give. This could replace the theory of sleep-apnic
snoring coevolving in conjunction with high carbohydrate diets, or it could stand beside it as additional
adaptation.
46 The most successful studies found reported 5% body weight lost through non-surgical means, maintained for 3 years. Even surgical weight loss provided lowered dependence on (but not independence from)
anti-diabetes drugs. See Kheniser, Saxon, and Kashyap (2021, 1854-66). Other studies reported similar
numbers over a similar time scale.
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modern life, they are not, of themselves, a cure.
A Brief Overview of Epigenetics
Epigenetics,47 sometimes known as non-Mendelian inheritance, refers to the
heritable changes in gene expression that occur without alterations to the underlying
DNA sequence. Epigenetic mechanisms regulate interactions between the genome
and environmental factors such as infection and nutritional changes. The three
primary epigenetic mechanisms currently being studied are DNA methylation, histone
modifications, and noncoding RNAs.
DNA methylation is a covalent addition of a methyl group to the cytosine residues
in CpG (5’-C-phosphate-G-3’) dinucleotides. While hypomethylation of CpG islands is
associated with gene activation, DNA methylation of promoter CpG islands is associated
with gene repression. In addition to transcriptional regulation, DNA methylation is
critical for maintaining genome integrity, most of the genome being highly methylated.
DNA methylation is not a stable epigenetic modification. It changes throughout the
lifespan of the organism, sometimes very rapidly, and dynamic DNA methylation
remodeling occurs during development and cell differentiation. DNA methylation is
catalyzed by DNA methyltransferases (DNMTs): DNMT3A and DNMT3B are de novo
methyltransferases. DNMT1 is involved in the maintenance of DNA methylation after
replication. Hydroxymethylation via 10–11 translocase (Tet) is the main mechanism for
demethylation.
Histone modifications alter chromatin compaction and the recruitment of
transcriptional regulators, modifying gene expression. Histone modification primarily
47 An excellent summary of DNA methylation and histone modifications can be found in Fodor, Cozma,
and Karnieli (2017, 531-49). Information on miRNAs can be found in Mishra, Zhong, and Kowluru (2014,
7256-65).
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refers to the acetylation or methylation of the N-terminal tail of a histone. Histone
acetylation on lysine residues leads to increased gene expression. H3K9ac, H3K14ac, and
H4K5ac are all marks associated with active transcription. Histone methylation is more
stable. Histone methylation can cause activation or repression of genes, depending on the
location of histone modification. H3K4me1/2/3 and H3K36me2/3 are transcriptionally
active, but H3K9me2/3 and H3K27me3 are repressive marks. There are many families of
histone-modifying enzymes, including histone deacetylases (HDACs), acetyltransferases
(HATs), methyltransferases (HMTs), and demethylases.
Noncoding RNAs include small noncoding RNAs, also known as miRNAs, which
are 21-25 nucleotides in length The category of noncoding RNAs also includes long
noncoding RNAs, or lncRNAs, which are more than 200 nucleotides in length. miRNAs
can bind to the 3’ untranslated region of target mRNA transcripts, disrupting translation
or leading to degradation. miRNAs provide a rapid but reversible regulation of about
60% of protein-coding genes. lncRNAs can control mRNA degradation and, unlike
miRNAs, can impact gene expression by means such as recruiting epigenetic modifier
proteins (such as transcription factors).
In addition to all of this, some epigenetic marks trigger other epigenetic marks:
histone acetylation, for instance, can trigger a change in the methylation of the associated
gene. Any disease that has genetic components that doesn’t manifest until adulthood may
be suspected of having an epigenetic component, or trigger. Diabetes, with its multitude
of associated genes but unclear lines of inheritance, is a clear suspect for epigenetically
triggered disease. Sleep apnea, also common in some ethnic groups but without clear
inheritance patterns, may also have a strong epigenetic component.
14

Hypothesis
This author hypothesizes that sleep apnea and diabetes coevolved, and if this is the
case, one would expect to see common epigenetic marks between the two conditions.

Methods
This section undertakes to present a review of extant literature regarding epigenetic
marks associated with diabetes and sleep apnea. While many of the marks surveyed
are unique to one of these conditions, there are several which appear in both of these
conditions which do not appear in healthy controls. After cleaning the data and entering
it in a database, sorting was done according to gene, protein/RNA expression, and
associated disorder(s).
Results and discussion
The following tables are selected from the dataset to show the overlapping epigenetic
marks between diabetes and sleep apnea. For the full dataset and useful extracts, please
see the appendices.
Genes Upregulated in both Sleep Apnea and Diabetes
AGT (angiotensin)
Protein
angiotensin
angiotensin

Histone/ Associated
RNA
condition
Sleep apnea
Diabetes

Specific epigenetic mark

Original source
paper
Hypomethylated enhancer Chu et al. (2015)
regions of AGT
Hypomethylation of AGT Marumo et al.
(2015)

The angiotensin promoter is hypomethylated in both sleep apnea and diabetes, leading
15

to increased expression of the angiotensin protein. Angiotensin is a vasoconstrictor48;
therefore, the increased production of angiotensin may be the reason behind the higher
blood pressures associated with these two conditions. The question that remains, then, is
how sleep apnea and diabetes induce this disruption of normal, homeostatic vasocontrol.
LEP (leptin)
Protein

Histone/
RNA

Associated
condition

Specific
epigenetic mark

Original source paper

Leptin

H4K20me
increased

diabetes

increased
methylation of
leptin H4K20
reduced leptin
promoter
methylation
leptin methylation
reduced
increased leptin
expression

Masuyama and
Hiramatsu (2012),
Masuyama et al (2015)
Jousse et al (2011)

Leptin

diabetes

Leptin

diabetes

Leptin

sleep apnea

Khalyfa et al (2013)
Gur et al (2016)

Leptin is a key player in the regulation of energy balance and body weight
control. Leptin is normally produced by certain types of adipose tissue and serves
as a sort of feedback regulator of fat storage, signaling satiety to the brain and also
signaling the body to stop storing fat when there is enough49. The existence of
“leptin-resistance,” akin to “insulin-resistance,” has been hypothesized on the basis
that humans with high levels of leptin as well as large fat deposits appear to resist the
hunger-damping signals of leptin50. Reduced methylation in the leptin promoter (see
table 1, above), seen in animal models of diabetes, is consistent with the increased
expression of leptin found in sleep apnea. Finally, increased methylation of the
48
49
50

The Human Protein Atlas, n.d.
Pan, Guo, and Su- 2014, 157-59
Król and Speakman 2007, 271-78
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histones around the leptin genes would also tend toward increased expression of the
gene product. This is a very consistent picture.
MMP-9
Protein
Matrix
metallopeptidase 9
Matrix
metallopeptidase 9
Matrix
metallopeptidase 9
Matrix
metallopeptidase 9
Matrix
metallopeptidase 9

Histone/
RNA
miR-21

Associated
condition
Sleep apnea
Diabetes

H3K9ac
increased
H3K9me2
decreased

Diabetes
Diabetes
Sleep apnea

Specific
epigenetic mark
upregulation of
miR-21
hypomethylation
of MMP-9
increased H3K9ac
on MMP-9
decreased
H3K9me2 on
MMP-9
increased MMP-9

Original
source paper
Zhang et al
(2018)
Kowluru et al
(2016)
Zhong and
Kowluru (2013)
Zhong and
Kowluru (2013)
Volná et al
(2011)

MMP-9 is also known (among other things) as matrix metallopeptidase 951.
MMPs are important in breakdown of the extracellular matrix and are involved in
such diverse processes as wound healing, learning, and memory52. In diabetes we
see an increased expression of this protein, as mediated by reduced methylation in
the promoter. We also see increased acetylation of H3K9, which is a transcriptionally
active mark, and decreased H3K9me2. Since H3K9me2 tends to repress transcription,
this reduction is also consistent with increased expression of MMP-9. Consistent with
a common etiology, Volna et al. found increased levels of MMP-9 in sleep apnea. The
over-expression of this protein could be the cause of slow diabetic wound healing and
the brain fog associated with sleep apnea, or the overexpression could be a result of the
body’s efforts to overcome those deficits, much as high insulin is generally a sign of poor
insulin uptake (insulin resistance) rather than a cause of high blood sugars, of itself.
51
52

https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=ShowDetailViej%27w&TermToSearch=4318
Parks 1998
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MMP-9 in humans has three fibronectin type II domains, which are collagen-binding
domains, which is especially interesting given that several collagen-binding miRNAs are
increased in diabetes53.
Genes Downregulated in both Sleep Apnea and Diabetes
SIRT1 (Sirutin), a class III HDAC (Histone deacetylase)
Protein

Histone/ RNA

Associated
condition

Sirtuin 1

miR-195

Diabetes

Sirtuin 1

miR-23b-3p

Diabetes

Sirtuin 1

Sleep apnea

Sirtuin 1

Diabetes

Specific
epigenetic
mark
Increased miR195
Increased miR23b-3p
Down-regulated
SIRT1
reduced
expression of
SIRT1

Original
source paper
Mortuza et al
(2016)
Mortuza et al
(2016)
Lin et al
(2018), Chen et
al (2015)
Chuang et al
(2011)

SIRT1 is a histone deacetylase that has been shown to be down regulated with
both sleep apnea and diabetes. Histone acetylation is generally an activating mark;
deacetylation would tend to reduce expression of the relevant gene. A reduction in active
deacetylases would tend toward upregulation of genes.
This is consistent with the findings of this paper, namely that more genes are
downregulated in both sleep apnea and diabetes than are upregulated. While possibly an
artifact of the limitations posed by the necessarily incomplete state of knowledge, it is,
nevertheless, a consistency.

53

See appendix
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Genes Regulated in Opposition to Each Other in Sleep Apnea and Diabetes
SOD2
Protein

Histone
Associated
modification or condition
RNA

Specific
Original source
epigenetic mark paper

Superoxide
dismutase 2

H3K4 decreased

Diabetes

decreased H3K4
across Sod2

Zhong and Kowluru
(2011), He et al
(2007).

Superoxide
dismutase 2

H3K9Ac increased

Diabetes

Increased H3K9ac on
Sod2

Zhong and Kowluru
(2011), He et al
(2007).

Superoxide
dismutase 2

H4K20me3 increased Diabetes

Increased H4K20me3
on Sod 2

Zhong and Kowluru
(2011), He et al
(2007).

Superoxide
dismutase 2

Sleep apnea

Hypermethylated
promoter regions of
Sod2

Nanduri et al (2017),
Nanduri et al (2012)

Superoxide
dismutase 2

Sleep apnea

DNA methylation
of Sod2 gene
incremented 6- and
12-fold

Nanduri et al (2012)

Superoxide
dismutase 2

Sleep apnea

Reduced expression of
Sod 2; increased DNA
methylation of Sod2

Nanduri et al (2017)

This enzyme is manganese-dependent and binds to the superoxide byproducts of
oxidative phosphorylation54. This mark is unusual, in that we’ve found contradictory
states between sleep apnea and diabetes: the increased methylation found in sleep apnea
would tend to reduce transcription, in direct opposition to the H3K9 acetylation found in
diabetic retinopathy, as H3K9 tends to promote active transcription. This contradiction
should put SOD2 in the crosshairs as a protein of interest in determining what is causing
damage and what is promoting repair in both diabetes and sleep apnea. The change in
activation status of this protein could signal a tipping point between diabetes and sleep
apnea, or the manganese-dependent nature of this protein could indicate that nutrition
status plays a role.
54

National Center for Biotechnology Information 2021, “Gene Search Results.”
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sRAGE(Soluble RAGE) and RAGE(MOK protein kinase)
Protein
Soluble RAGE
(sRAGE)
MOK protein
kinase

Histone
Associated
modification or condition
RNA
Sleep apnea
H3K27me3
decreased

Diabetes

MOK protein
kinase

H3K9/14Ac
increased

Diabetes

MOK protein
kinase

H3K9me2 decreased

Diabetes

MOK protein
kinase

H3K9me3 decreased

Diabetes

Specific
epigenetic
mark
Low levels of
sRAGE
decreased
H3K27me3
over RAGE
Increased
H3K9/14Ac on
RAGE
decreased
H3K9me2 over
RAGE
decreased
H3K9me3 over
RAGE

Original
source paper
Volná et al
(2011)
Reddy et al
(2014).
Reddy et al
(2014).
Reddy et al
(2014).
Reddy et al
(2014).

RAGE belongs to the MAP kinase superfamily. In diabetes, we see a reduction in
specific epigenetic markers (H3K9me2, H3K9me3, and H3K27me3) which normally
repress expression55. Reduction of those markers would tend toward increased expression
of RAGE. In sleep apnea, we see lower levels of sRAGE than would be expected.
From the abstract of Al Rifai et al. (2015): “Advanced glycation end products (AGEs)
may cause inflammation by binding to their cellular receptors (RAGE). Soluble RAGE
(sRAGE) acts as a decoy receptor for AGEs and may prevent inflammation.” While
RAGE and sRAGE are not the same marker, this is an example of the two conditions
having biochemical interactions that play off of each other in important ways. Curiously,
RAGE is also regulated by CDX2 (Caudal type homeobox 2), which binds preferentially
to methylated DNA.56
55
56

Punt, Stranford, Jones, and Owen 2018, 639
https://www.proteinatlas.org/ENSG00000165556-CDX2
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FOXP3(scurfin)
Protein
scurfin,
forkhead box
P3
scurfin,
forkhead box
P3

Histone/
RNA

Associated
condition
Sleep apnea

Diabetes

Specific
epigenetic mark
Hypermethylated
intron1 region
(mean of 11 CpG
sites)
FOXP3 mRNA
more highly
expressed
in Diabetic
patients without
nephropathy than
in those with
nephropathy or in
healthy controls.

Original
source paper
Kim et al.
(2012)
Telikani et al.
(2019)

Foxp3 is both “necessary and sufficient to induce differentiation to the TREG
lineage.” TREGs are understood to reduce autoimmunity, though the mechanism is not
well understood. What makes this protein especially interesting is that diabetics with
nephropathy express Foxp3 at similar rates to controls. In diabetics without nephropathy,
however, Foxp3 is expressed at much higher levels than in controls (diabetics with
diagnosed sleep apnea were excluded from this study). In patients with sleep apnea, on
the other hand, Foxp3 is hypermethylated, leading to downregulation. This suggests a
situation where sleep apnea could be the body’s attempt to counteract the negative effects
of metabolic syndrome. The reverse, of course, may also be true.
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miRNAs Found to be Associated with Diabetes and Sleep Apnea
miR-26b
notes

associated
RNA

Associated
condition

miR-26b

Diabetes

Promote cognitive miR-26b
dysfunction

Sleep apnea

Specific
epigenetic
mark
change in
miR-26b
upregulation
of miR-26b

original source
paper
Khurana et al (2019)
Gao et al (2017)

Gao et al. (2017) inform us that miR-26b is believed to be crucial in the process of
OSA-induced cognitive dysfunction and that miR-26b is upregulated with intermittent
hypoxia in rats (used as a model for sleep apnea in humans). Khurana et al. (2019) inform
us that miR-26b expression changes in diabetes as well57. Perhaps this also provides a
window to some of the cognitive deficits associated with diabetes.
miR-31
Gene
or gene
target

Protein

notes

RNA

condition

Specific
epigenetic
mark

original
source
paper

PKCε

Protein kinase C
epsilon

Promotes cardiac
hypertrophy

miR-31

Sleep apnea

upregulation of
miR-31

Ren et al
(2018)

VEGF

Vascular
endothelial
growth factor A

miR-31

Diabetes

Increased miR31

Kovacs et al
(2011)

Low levels of this RNA are associated with gastric cancer invasion and
metastasis58. Given that this miRNA is upregulated in both sleep apnea and diabetes,
in combination with the nutritional component of diabetes, and the question is raised:
What evolutionary advantage is conferred by diabetes? A ubiquitous phenotype must
57 The reader doubtless joins the author in preferring to know in what direction this miR expression
changes in diabetes. The information that miR-107 changes comes from Khurana et al. (2019); neither
source nor methodology were cited, and alas the direction of change remains unknown.
58 National Center for Biotechnology Information 2021, “MIR 31 microRNA 31 [Homo sapiens (human)]”
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generally be considered advantageous in some circumstances. What advantage does a
diabetes-prone phenotype confer?
miR-107
RNA

Associated
condition
Diabetes
Sleep apnea

miR-107
mir-107

Specific epigenetic
mark
change in miR-107
Downregulation of
miR-107

original source
paper
Khurana et al (2019)
Li et al (2017)

Zhang et al. (2021) found that miR-107 contributes to inflammatory pain, probably
by reducing GLT-1 expression. The fact miR-107 is down-regulated in sleep apnea and
changes59 in diabetes raises the question: Is miR-107 in any way implicated in diabetic
neuropathy? Is a patient with sleep apnea and diabetes more or less likely to experience
diabetic neuropathy? These are important questions for further study.

miR-155
Gene
or gene
target

Gene
aliases

Protein

notes

RNA

Associated Specific
condition epigenetic
mark

original
source
paper

FOXO3a

FOXO3
(AF6q21,
FKHRL1,
FOXO2,
FOXO3A)

Forkhead
box O3

Promote
kidney
injury

miR-155

Sleep apnea

upregulation Wu et al
of miR-155 (2018)

NF-kB

NFKB1
(KBF1,
NF-kappaB,
NF-kB1,
NFkappaB,
NFKB-p50,
p105, p50)

Nuclear
factor kappa
B subunit 1

miR-155

Diabetes

Increased
miR-155

Kovacs et
al (2011)

According to Mahesh and Biswas (2019), highly conserved miRNA 155 is a master
regulator of inflammatory diseases, including cancer and lung disease. Furthermore, this
miRNA is upregulated in both sleep apnea and diabetes.
59

See the note on miR-26b, above
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Cascades
FOXO4 (Forkhead box 04), IGFBP1(Insulin like growth factor binding protein 1), IGF-1
(Insulin like growth factor 1), and IGF-2 (Insulin like growth factor 2)
Protein

Histone/RNA

Forkhead box O4
Forkhead box O4

H3K9Ac increased

Insulin like growth
factor 1

Insulin like growth
factor 1

H3K4me reduced

Insulin like growth
factor 2

Associated
condition

Specific epigenetic Original source
mark
paper

Diabetes

increased expression
of gene

Chuang et al (2011)

Sleep apnea

Increased H3K9Ac
enrichment over
FOXO4

Cortese et al (2017)

Diabetes

Decreased
methylation of IGF-1

"Goodspeed et al
(2015)
growth-restricted
rats. FASEB J. 29
(3), 807e819."

Diabetes

IGF1 H3K4me
reduced

Tosh et al (2010)

Diabetes

reduced methylation
of IGF2

Heijmans et al (2008)

FOXO4 is a transcription factor which can activate IGFBP160, a binding factor which
prolongs the half-life of IGFs. IGF-1 and IGF-2 are also upregulated in diabetes61.
NF-κB (Nuclear factor kappa-light-chain-enhancer of activated B cells), TNF-α (Tumor
necrosis factor alpha), assorted miRNAs
Protein

Histone/ RNA

Nuclear factor miR-132
kappa B subunit
1
Nuclear factor miR-146
kappa B subunit
1
Nuclear factor miR-155
kappa B subunit
1

Associated
condition

Specific
epigenetic
mark
Increased miR132

Original
source paper

Diabetes

Increased miR146

Kovacs et al
(2011)

Diabetes

Increased miR155

Kovacs et al
(2011)

Diabetes

Kovacs et al
(2011)

60 https://www.proteinatlas.org/ENSG00000146678-IGFBP1. This author has found no references to
epigenetic marks directly regarding IGFBP1.
61 Of some interest here is the fact that not only are Fox03, Fox04, and Foxp3 disregulated in diabetes, but
Foxp2 is necessary to human speech. An intriguing avenue for future study. See https://www.proteinatlas.
org/ENSG00000128573-FOXP2 .
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Protein

Histone/ RNA

Associated
condition

Specific
epigenetic
mark
Increased miR21

Original
source paper

Nuclear factor miR-21
kappa B subunit
1
Nuclear factor
kappa B subunit
1

Diabetes
Sleep apnea

increased
nuclear factorkB

Ryan et al
(2006)

Tumor necrosis miR-452
factor
Tumor necrosis
factor
Tumor necrosis
factor

Sleep apnea

downregulation
of miR-452
increased level
of TNF-α
increased
nuclear factor-k
β, TNF-α, and
IL-8

Uchiyama et al
(2019)
Khurana et al
(2019)
Gur et al (2016)

Sleep apnea
Sleep apnea

Kovacs et al
(2011)

NF-κB is a transcription factor that controls cytokine production and cell survival and
shows up in elevated levels in both diabetes and sleep apnea. Kovacs et al. (2011) show
that miRNA-146 can act as negative feedback regulator of NF-κB in diabetes and suggest
its use as a therapeutic agent against the overexpression of NF-κB. An important direction
for future research might be exploring the effects of such therapies not only on diabetes
but on sleep apnea.
Ryan et al. (2006) describe TNF-α as NF-κB-dependent and note that it is elevated
in sleep apnea. TNF-α is a cytokine used by the immune system and is released by
macrophages as part of an inflammatory response to infection62. While NF-κB shows up
in searches of epigenetic marks in OSA and diabetes, TNF-α shows up only in searches
of epigenetic marks related to sleep apnea. Nevertheless, given this context, it seems
probable that such epigenetic marks exist, though the relevant research may not yet have
been done.
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miR-29c and the miR-21/Spry1/ERK/MMP-9 signaling pathway

Gene
or gene
target

Gene aliases

Protein

ERK

extracellularsignalregulated
kinase

MMP-9

MMP9
(CLG4B)

Matrix
metallopeptidase
9

NF-kB

NFKB1
(KBF1,
NF-kappaB,
NF-kB1,
NFkappaB,
NFKB-p50,
p105, p50)

Nuclear factor
kappa B subunit 1

PTEN/
PI3K/
AKT

notes

RNA

Associated Specific
condition epigenetic
mark

original
source
paper

Induce atrial miR-21
remodeling
and fibrosis

Sleep apnea

upregulation Zhang et
of miR-21
al (2018),
Wang et al
(2018)

Induce atrial miR-21
remodeling
and fibrosis

Sleep apnea

upregulation Zhang et
of miR-21
al (2018),
Wang et al
(2018)

Diabetes

Increased
miR-21

Induce atrial miR-21
remodeling
and fibrosis

Sleep apnea

upregulation Zhang et
of miR-21
al (2018),
Wang et al
(2018)

miR-21

Kovacs et al
(2011)

Spry1

SPRY1
(hSPRY1)

Sprouty RTK
signaling
antagonist 1

Induce atrial miR-21
remodeling
and fibrosis

Sleep apnea

upregulation Zhang et
of miR-21
al (2018),
Wang et al
(2018)

Spry1

SPRY1
(hSPRY1)

protein sprouty
homolog 1;
Sprouty RTK
signaling
antagonist 1

Induce atrial miR-21
remodeling
and fibrosis

Sleep apnea

upregulation Zhang et al
of miR-21
(2018)

VEGF

VEGFA
(VEGF,
VEGF-A,
VPF)

Vascular
endothelial
growth factor A

miR-21

Diabetes

Increased
miR-21

miR-21

Diabetes

Spry1

SPRY1
(hSPRY1)

protein sprouty
homolog 1;
Sprouty RTK
signaling
antagonist 1

miR-29c Diabetes
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Kovacs et al
(2011)

Khurana et
al (2019)
Increased
miR-29c

Long et al
(2011)

Long et al (2011) found that miRNA-29c is upregulated in diabetes. They also
found that miR-29c is almost perfectly complementary to Spry1 (the gene that produces
the Sprouty homolog 1 protein). Furthermore, they established that knockdown of
miRNA-29c by an antisense oligonucleotide has great promise in preventing kidney
damage in diabetic patients. Zhang et al. (2018) showed the upregulation of MiR-21
with intermittent hypoxia. MiR-21 has been shown to be involved in arrhythmia and
myocardial fibrosis; Spry1 is a downstream target of miR-21. The upregulation of miR-21
in sleep apnea, therefore, provides a good window into the etiology of cardiac problems
associated with sleep apnea. The fact that both sleep apnea and diabetes induce changes
in miRNA profiles associated with the Spry1/ERK/MMP-9 signaling pathway suggests a
set of possible therapeutic targets with the potential to address health issues arising from
both conditions. Other miRNAs outside of this pathway are also affected by sleep apnea
and diabetes63. Certainly VEGF (as it is also associated with miR-21) should be examined
as part of this pathway.
Conclusions
There are clearly a number of epigenetic marks common to sleep apnea and diabetes
which are not common to healthy controls. We’ve focused here on DNA methylation,
miRNAs, and histone modifications, but it’s interesting to note that histone positioning
and other epigenetic factors could also play a role in the pathogenesis of these conditions.
Whether the two conditions arise from a common root cause, or whether they are two
faces of the same condition, the possibility of coevolution has not been ruled out and
remains an intriguing idea for further investigation.
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It is perhaps helpful to speculate, here.

One complex model of lifestyle diseases
Metabolic
syndrome
& diabetes

Light pollution
and disrupted
sleep cycles
Ultra-Processed
Food

Protective obesity
Susceptible
individuals

Pollution

Sleep
apnea

Epigenetics of
lifestyle disease

Viruses,
inherited
epigenetics,
other factors

Diseases of
modern life

Etc.
Heart
Disease

Stroke

Figure 2 An indicative model of lifestyle disease. While
simplicity is generally preferred, the complexity of this model is
outweighed by the fact that it does not contradict the data in hand.

One possible route to diabetes might go like this: Light pollution disrupts the sleep
cycle, throwing the immune system into difficulty. The chaotic immune system is unable
to repair the microbiome, which is also under multiple assault from UPFs, lacking
nutrients to properly build the body, and taking on preservatives which continue to
do their job, even inside the body, namely: killing bacteria. As this multi-front assault
proceeds, the body begins to pack on fat deposits, developing both leptin and insulin
resistance in the process. This is a protective mechanism, protecting other body systems
from metabolic assault. The poor nutrition from UPFs makes it harder for the body to
produce insulin receptors and other needed proteins, hastening progression into fullblown metabolic syndrome. To offset some of the problems of metabolic syndrome, sleep
apnea begins to manifest. Eventually, the protective mechanisms of obesity and sleep
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apnea fail, and blood teeter out of homeostatic equilibrium. Continued air pollution tips
the scale into a spiral, landing in full-blown diabetes.
Another possibility: Metabolic syndrome is triggered by some combination of
overwork and undernutrition64; sleep apnea itself causes homeostatic glucose control
to break, and the cascade begins. Again, obesity is part of this cascade, but (again) as a
protective measure. In this scenario, obesity is still a measure of poor health – but curing
obesity will no more cure the underlying health problems than removing blood from the
skin will cure a gut wound.
Another possible route: Social stressors cause a constant assualt of cortisol on body
tissues, particularly heart tissue. The body triggers sleep apnea to repair it. The sleep
apnea disturbs the immune system and thus the microbiome; the body, in an attempt to
regulate and repair all this damage, starts storing up adipose tissue. In this scenario, UPFs
then provide the perfect storm of poor fuel under external stressors to throw blood sugar
regulation out the metaphorical window.
One last possiblity: Chemical exposure (possibly through air pollution) causes the
body to pack on fat deposits, as a way to safely store those chemicals away from (literal)
circulation. Those fat deposits might trigger leptin resistance, then insulin resistance, and
so forth. Note that this is very similar to a conventional view of obesity and diabetes,
outlined at the beginning of this paper, with the exception that it recognizes that not all
causes of obesity are based on individual choices.
Other possible routes to metabolic syndrome can be envisioned, using the data
available to us. Clearly, further rigorous research is needed. Whatever the case, solving
this question—using real data rather than imagined scenarios—can change people’s lives.
64 While undernutrition often refers to a lack of calories, here it is used to indicate a lack of any essential
nutrient, including fiber, minerals, and any other nutrient or vitamin necessary for healthy functioning.
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tested

Gen.

CRP levels in

Histone

RNA or

"""Heightened

notes

OSA

OSA

OSA

OSA

paper as

described in

CRP

Increased level of

CRP

Increased level of

CRP

Increased level of

CRP

Increased level of

mark

Specific epigenetic

Qian et al (2012)

et al (2010)"

"Matthews

Li et al. (2016)

al (2004)

Guilleminault et

original paper

(2012)

Qian et al.

et al. (2010)"

"Matthews

Li et al. (2016)

et al. (2004)

Guilleminault

reference

review paper

(2019)

Khurana et al

(2019)

Khurana et al

(2019)

Khurana et al

(2019)

Khurana et al

review paper
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Connective tissue
growth factor

CRP (PTX1)

CRP (PTX1)

CTGF (CCN2,

IGFBP8)

CRP

CRP

CTGF

C-reactive protein

C-reactive protein

C-reactive protein

CRP (PTX1)

CRP

C-reactive protein

C-reactive protein

CRP (PTX1)

CRP (PTX1)

CRP

C-reactive protein

Protein

CRP

CRP (PTX1)

Alias(es)

Description,

CRP

Gene

H3K9me

apnea

patients with

increased

significantly

w. genes

mRNA associated

decreased

Diabetes

apnea

Sleep

apnea

women
High levels

Sleep

apnea
Increased in

increased in men

matched controls"

with healthy""

patients compared

Sleep

apnea

levels in pri- mary
snorers and OSAS

Sleep

"""Higher CRP

without OSA."""

compared to those

levels of CRP as

significantly higher

OSA had

Sleep

"""Non-obese

CRP levels"""

pro- portional to

Severity of OSA

a risk for CVD’s

con- trols; suggest

compared with

patients with OSA

apnea

condition

Associated
Sleep

tested

Gen.

higher in

Histone

RNA or

"""CRP levels

notes

nephropathy

Diabetic

OSA

OSA

OSA

OSA

OSA

OSA

paper as

described in

on CTGF

Decreased H3K9me

Increased hsCRP

increased hsCRP

and leptin

6, insulin resistance,

increased hsCRP, IL-

CRP

Increased level of

CRP

Increased level of

CRP

Increased level of

mark

Specific epigenetic

Sun et al (2010)

Volná et al (2011)

Gur et al (2016)

Gur et al (2016)

Zikari et al (2016)

et al (2015)"

"Thunstrom

al (2002)

Shamsuzzaman et

original paper

58

(2016)

Zikari et al.

et al. (2015)"

"Thunstrom

et al. (2002)

Shamsuzzaman

reference

review paper

(2017)

Fodor et al

(2019)

Khurana et al

(2019)

Khurana et al

(2019)

Khurana et al

review paper
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(dJ483K16.1,

ERK

eNOS

eNOS

eNOS

elongase 5

ELOVL5

ELOVL5

synthase

synthase

synthase 3, NOS3

synthase

synthase 3, NOS3

remodeling and
fibrosis

Induce atrial

regulated kinase

apnea

Sleep

apnea

Sleep

IHR

OSAab

eNOS mRNA

miR-21

upregulation of

(-171)

core promoter region

CpG sites in eNOS

hypermethylated

group

group vs. OSAn

decreased in OSAab

levels significantly

OSAab group;

eNOS gene

CpG in core

Hypermethylated

(-171 CpG site)

promoter region

Hypermethylated

ELOVL5

methylation of

Increased

Cyp7a1

methylation across

increased H3K9

Cyp7a1

Acetylation across

decreased H3K9

Cyp4a10

Hypomethylation of

mark

Specific epigenetic

of eNOS gene in

with high CRP

Pediatric OSA

OSA/IHR

syndrome

Metabolic

syndrome

Metabolic

syndrome

Metabolic

nephropathy

diabetic

paper as

described in

promoter region of

apnea

Sleep

apnea

Sleep

Diabetes

Diabetes

Diabetes

Diabetes

condition

Associated

changes in the core

PO

F1

F1

F1

tested

Gen.

promoter region

miR-21

Histone

RNA or

for epigenetic

DNA analyzed

Blood genomic

gene expression

Decreased eNOS

acid

Unsaturated fatty

low protein

low protein

Hypomethylation

notes

extracellular-signal-

(ECNOS, eNOS)

endothelia nitric oxide

Nitric oxide

(ECNOS, eNOS)

endothelia nitric oxide

Nitric oxide

(ECNOS, eNOS)

endothelia nitric oxide

synthase 3, NOS3

member 1

family 7 subfamily A

Cytochrome P450

Nitric oxide

HELO1, SCA38)

ELOVL fatty acid

CYP7A1 (CYP7)

Cyp7a1

member 1

family 7 subfamily A

Cytochrome P450

member 10

family 4 subfamily A

Cytochrome P450

Protein

CYP7A1 (CYP7)

Alias(es)

Description,

Cyp7a1

Cyp4a10

Gene

al (2018)

(2018), Wang et

Zhang et al

Gozal et al (2013)

Kheirandish-

Gozal et al (2013)

Kheirandish-

Gozal et al (2013)

Kheirandish-

Hoile et al (2014)

Sohi et al (2011)

Sohi et al (2011)

(2015)

Marumo et al

original paper

69,70

(17)

Gozal et al.

Kheirandish-

80

2014)

(Hoile et al.,

2011)

(Sohi et al.,

2011)

(Sohi et al.,

69

reference

review paper

(2019)

Chen et al

al (2018)

Perikleous et

(2019)

Chen et al

(2017)

Park et al

(2017)

Park et al

(2017)

Park et al

(2017)

Fodor et al

review paper
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2

DES6, FADSD6,

FOXO4

FOXO4

MLLT7)

FOXO4 (AFX1,

MLLT7)

FOXO4 (AFX1,

FOXO3A)

FKHRL1, FOXO2,

Forkhead box O4

Forkhead box O4

Forkhead box O3

FOXO3a

FOXO3 (AF6q21,

fibronectin

fibronectin

FN

FN

fibrinogen

SLL0262, TU13)

LLCDL2,

Fatty acid desaturase

FADS2 (D6D,

SLL0262, TU13)

FG

FADS2

2

DES6, FADSD6,

LLCDL2,

Fatty acid desaturase

FADS2 (D6D,

FADS2

Endothelin 1

Protein

EDN1 (ET1)

Alias(es)

Description,

ET-1

Gene

Bcl2ll

transcription of

for binding and

Foxo4, necessary

acetylation of

increases lysine

AGE probably

Foxo4 ^Bcl2ll;

^AGE causes ^

higher sugar causes

mark

Activating histone

injury

Promote kidney

High levels

acid

Unsaturated fatty

acid

Unsaturated fatty

notes

increased

H3K9Ac

miR-155

miRNA-146a

F1

Diabetes

apnea

Sleep

apnea

Sleep

Diabetes

Diabetes

apnea

Sleep

Diabetes

Diabetes

Diabetes

CIH

IHR

of gene

increased expression

FOXO4

enrichment over

Increased H3K9Ac

miR-155

upregulation of

across FN promoter

Histone acetylation

146a

Diabetes

Decreased miRNA-

retinopathy

expression

High fibrinogen

FADS2

methylation of

Increased

FADS2

methylation of

Increased

at promoter of ET-1

Histone acetylation

mark

Specific epigenetic

diabetic

OSA

syndrome

Metabolic

syndrome

Metabolic

of diabetes

macrovascular

paper as

described in

promoter

Diabetes

condition

Associated

complications
F1

tested

Gen.

acetylation at

Histone

Histone

RNA or

(2011)

Chuang et al

(2017)

Cortese et al

Wu et al (2018)

Chen et al (2010)

Bae (2013)

Volná et al (2011)

Hoile et al (2014)

Hoile et al (2013)

Chen et al (2010)

original paper

58

72

131

130

2014)

(Hoile et al.,

2013)

(Hoile et al.,

131

reference

review paper

(2019)

Chen et al

(2019)

Chen et al

(2017)

Fodor et al

(2017)

Fodor et al

(2017)

Park et al

(2017)

Park et al

(2017)

Fodor et al

review paper
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G6PC

G6PC

G6PC

G6PC

FOXP3

FOXP3

FOXP3

Gene

H3Ac across

Sleep

Diabetes

condition

Associated

OSA

T2DM

paper as

described in

highly expressed

FOXP3 mRNA more

mark

Specific epigenetic

box P3

DIETER, IPEX,

phosphatase catalytic

GSD1a)

phosphatase catalytic

GSD1a)

phosphatase catalytic

GSD1a)

phosphatase catalytic

GSD1a)
subunit

Glucose-6-

G6PC (G6PT,

subunit

Glucose-6-

G6PC (G6PT,

subunit

Glucose-6-

G6PC (G6PT,

subunit

Glucose-6-

G6PC (G6PT,

maternal diet

low protein

maternal diet

low protein

maternal diet

low protein

maternal diet

low protein

CRP levels

correlated with

SCURFIN, XPID)

methylation levels
were closely

box P3

DIETER, IPEX,

FOXP3 DNA

scurfin

either FOXP3 or

JM2, PIDX,

scurfin, forkhead

FOXP3 (AIID,

SCURFIN, XPID)

JM2, PIDX,

scurfin, forkhead

FOXP3 (AIID,

decreased

H3K9me

increased

H3K4me

increased

the promoter

F1

F1

F1

F1

Diabetes

Diabetes

Diabetes

Diabetes

apnea

Sleep

apnea

syndrome

Metabolic

syndrome

Metabolic

syndrome

Metabolic

syndrome

Metabolic

with high CRP

Pediatric OSA

(pediatric)

G6PC

methylation of

decreased

H3K9 on G6PC

methylation of

Decreased

H3K4 on G6PC

methylation of

Increased

G6PC

acetylation of H3 on

Increased

FOXP3

methylation of

increased

of 11 CpG sites)

intron1 region (mean

Hypermethylated

healthy controls.

nephropathy or in

than in those with

without nephropathy

PO

tested

Gen.

SCURFIN, XPID)

product called

decreased

Histone

RNA or

in Diabetic patients

box P3

notes

JM2, PIDX,

scurfin, forkhead

DIETER, IPEX,

Protein

FOXP3 (AIID,

Alias(es)

Description,

(2008)

Jia and Chen

Jia et al. (2012)

Jia et al. (2012)

Jia et al. (2012)

Kim et al (2012)

Kim et al (2012)

(2019)

Telikani et al

original paper

2012)

(Jia et al.,

2012)

(Jia et al.,

2012)

(Jia et al.,

2012)

(Jia et al.,

Kim et al. (16)

(16); 79

42; Kim et al.

reference

review paper

(2017)

Park et al

(2017)

Park et al

(2017)

Park et al

(2017)

Park et al

al (2018)

Perikleous et

(2019)

Chen et al

al (2018) and

Perikleous et

(2016),

Gur et al

review paper
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GLUT4

GCLC

GCLC

GCLC

GAX

GABPA

Gene

transcription factor
alpha subunit

E4TF1A, NFT2,

protein as Gulch,

subunit

protein as Gulch,

subunit

SLC2A4 (GLUT4)
member 4

Solute carrier family 2

protein as Gulch,

subunit

low protein

lists as GCLC

but original article

has typo, listing

ligase catalytic

GLCL, GLCLC)

review article

Glutamate-cysteine

GCLC (GCS,

lists as GCLC

but original article

has typo, listing

ligase catalytic

GLCL, GLCLC)

review article

Glutamate-cysteine

GCLC (GCS,

lists as GCLC

but original article

has typo, listing

review article

ligase catalytic

GLCL, GLCLC)

hypertension

pulmonary

potentiates

GAX, which

miR-130a targets

Glutamate-cysteine

homeobox,

specific homeobox

processes

anti-inflammatory

contributes to

factor which

transcription

dysfunction; a

endothelial

Attenuate

notes

GCLC (GCS,

growth arrest-specific

Growth arrest-

NRF2, NRF2A)

GA binding protein

(E4TF1-60,

Protein

NRF2 aka GABPA

Alias(es)

Description,

H3Ac increased

decreased

H3K4me3

increased

H3K4me2

decreased

H3K4me

miR-130a

miR-630

Histone

RNA or

D38

female

F1

tested

Gen.

Diabetes

Diabetes

Diabetes

Diabetes

apnea

Sleep

apnea

Sleep

condition

Associated

syndrome

Metabolic

retinopathy

diabetic

retinopathy

diabetic

retinopathy

diabetic

IHR

IHR

paper as

described in

GLUT4

Acetylation on

Increase of H3

H3K4me3 on GCLC

Decreased

increased H3K4me2

H3K4me1 on GCLC

Decreased

miR-130a

Up regulation of

miR-630

downregulation of

mark

Specific epigenetic

(2012)

Zheng et al

(2014)

Mishra et al

(2014)

Mishra et al

(2014)

Mishra et al

An et al (2017)

(2016)

Khalyfa et al

original paper

2012)

(Zheng et al.,

84

84

84

62

27

reference

review paper

(2017)

Park et al

(2017)

Fodor et al

(2017)

Fodor et al

(2017)

Fodor et al

(2019)

Chen et al

(2019)

Chen et al

review paper

64

SLC2A4 (GLUT4)

SLC2A5 (GLUT5)

GPX2 (GSHPX-GI)

GLUT4

Glut5

GPX2

GR

GR

GR

SLC2A4 (GLUT4)

Alias(es)

Description,

GLUT4

Gene

F1

test subject; mark

receptor

test subject; mark

receptor

test subject; mark

receptor
offspring

found in adult

Undernutrition in

Glucocorticoid

offspring

found in adult

Undernutrition in

Glucocorticoid

offspring

found in adult

Undernutrition in

Glucocorticoid

expression

increased

decreased

H3K27me

increased

F1

F1

diabetes

diabetes

diabetes

metabolic

IH
of Sod1, Sod 2,

"reduced expression

Glut5

Hypomethylation of

syndrome

metabolic

syndrome

metabolic

syndrome

GR reduced

DNA methylation of

of H3K27 on GR

Reduced methylation

of H3K9 on GR

Increased acetylation

recovery"

after 30 days of

Sod2, Txnrd2, Prdx4

methylation of Sod1,

increased DNA

vs. controls

apnea

Sleep

diabetic
nephropathy

Txnrd4, Gpx2)

H3K9Ac

PO

Diabetes

GLUT4

Increase of H4

increase on GLUT4

H3K4 Methylation

mark

Specific epigenetic

D38

diabetes

diabetes

paper as

described in

Acetylation on

diabetes

diabetes

condition

Associated

female

F1

D38

female

F1

tested

Gen.

Txnrd2, and Prdx4

analyzed (Sod1,

H4Ac increased

increased

H3K4me

Histone

RNA or

Sod2, Cat, Txnrd2,

– AOE genes were

peroxidase 2

Hypomethylation

low protein

low protein

notes

Glutathione

member 5

Solute carrier family 2

member 4

Solute carrier family 2

member 4

Solute carrier family 2

Protein

(2013)

Begum et al

(2013)

Begum et al

(2013)

Begum et al

(2017)

Nanduri et al

(2015)

Marumo et al

(2012)

Zheng et al

(2012)

Zheng et al

original paper

2013)

(Begum et al.,

2013)

(Begum et al.,

2013)

(Begum et al.,

(19)

Nanduri et al.

69

2012)

(Zheng et al.,

2012)

(Zheng et al.,

reference

review paper

(2017)

Park et al

(2017)

Park et al

(2017)

Park et al

al (2018)

Perikleous et

(2017)

Fodor et al

(2017)

Park et al

(2017)

Park et al

review paper
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generation

life from the

HSP60

HIP/PAP

HDAC4

implicated in

family D (Hsp60)
member 1

assembly.

macromolecular

protein import and

mitochondrial

chaperonin

Heat shock protein

HSP60, SPG13)

Hsp60 is a

resistance

Potentiate insulin

HSPD1 (GroEL,

REG-III, REG3)

member 3 alpha

induced diabeteic

KIAA0288)
Regenerating family

streptozotocin

HDACA,

PAP1, PBCGF,

hippocampus of

4, HDAC-A,

REG3A (HIP, PAP,

HDAC4 in

HD4, HDAC-

mice

expression of

Decreased

expression

a tag for epigenetic

deacetylation gives

HA6116,

HDAC4 (BDMR,

YAF1)

HDAC)

HDAC2 (RPD3,

(Class I

life.

in early neonatal

thereafter repressed

Histone deacetylase 4

mark found in F2

expressed in fetal

Histone

in test subject;

maternal allele and

Undernutrition

notes

noncoding RNA

Histone deacetylase 2

Protein

H19 is a long

Alias(es)

Description,

HDAC2

H19

Gene

miR-1

miR-203

involvement

general histone

involvement

general histone

Histone

RNA or
F2

tested

Gen.

Diabetes

apnea

Sleep

Diabetes

apnea

Sleep

Diabetes

condition

Associated

of diabetes

complications

macrovascular

IHR

(animal)

Diabetes

IHR

syndrome

Metabolic

paper as

described in

miR-206

Increased miR-1 and

miR-203

downregulation of

HDAC4

downregulation of

Up-regulated

in the liver

methylation of H19

Increased

mark

Specific epigenetic

Shan et al (2010)

(2019)

Uchiyama et al

(2013)

Thomas et al

Chen et al (2015)

(2016)

Rodriguez et al

Gonzalez-

original paper

94

74

57

al., 2016)

Rodriguez et

(Gonzalez-

reference

review paper

(2017)

Fodor et al

(2019)

Chen et al

(2019)

Chen et al

(2017)

Park et al

review paper
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IL-1β

IL-1α

IL-17

IL-13

IGF2

BETA, IL1F2)

IL1B (IL-1B, IL1-

IL1F1)

IL1, IL1-ALPHA,

IL1A (IL-1A,

17, IL-17A, IL17)

IL17A (CTLA8, IL-

Interleukin 1 beta

Interleukin 1 alpha

expression

Increased

expression

Increased

and IL17RC

Ligand for IL17RA

production

MGC116788,
Interleukin 17A

cytokine

MGC116786,

MGC116789, P600)

inflammatory

Inhibits

offspring

found in adult

test subject; mark

Undernutrition in

adult offspring

mark found in

pregnant subject;

Undernutrition of

adult offspring

mark found in

Methyl-rich diet;

increased

this cytokine was

assembly.

macromolecular

protein import and

BHR1, IL-13,

Interleukin 13

factor 2

FLJ44734, IGF-II)

IL13 (ALRH,

Insulin like growth

factor 1

IGF1A, IGFI)

IGF2 (C11orf43,

Insulin like growth

IGF1 (IGF-I,

factor 1

IGF1A, IGFI)

IGF1

Insulin like growth

IGF1 (IGF-I,

IGF-1

Interferon gamma

member 1

IFNG

implicated in

family D (Hsp60)
mitochondrial

chaperonin

Heat shock protein

Hsp60 is a

notes

HSP60, SPG13)

Protein

HSPD1 (GroEL,

Alias(es)

Description,

IFNγ

HSP60

Gene

reduced

H3K4me

miR-206

Histone

RNA or

F1

F1

tested

Gen.

apnea

Sleep

apnea

Sleep

Diabetes

apnea

Sleep

Diabetes

Diabetes

Diabetes

Diabetes

Diabetes

condition

Associated

animals)

(CIH in

Sleep apnea

animals)

(CIH in

Sleep apnea

T2DM

animals)

(CIH in

Sleep apnea

syndrome

Metabolic

syndrome

Metabolic

syndrome

Metabolic

T2DM

of diabetes

complications

macrovascular

paper as

described in

IL-1β increased

IL-1α increased

IL-17 increased

IL-13

increased levels of

of IGF2

reduced methylation

reduced

IGF1 H3K4me

IGF-1

methylation of

Decreased

increased

IFN-gamma

miR-206

Increased miR-1 and

mark

Specific epigenetic

Lee et al (2017)

Lee et al (2017)

(2019)

Telikani et al

Lee et al (2017)

(2008)

Heijmans et al

Tosh et al (2010)"

"

(2015)

Goodspeed et al

(2019)

Telikani et al

Shan et al (2010)

original paper

al., 2008)

(Heijmans et

2010)"

(Tosh et al.,

"

al., 2015

Goodspeed et

94

reference

review paper

(2017)

Park et al

(2017)

Park et al

(2017)

Park et al

(2017)

Fodor et al

review paper
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INS

IL1R2

IL-8

IL-6

IL-6

IL-6

IL-6

IL-6

IL-4

Gene

IDDM2)

insulin

type 2

INS (IDDM1,

Interleukin 1 receptor

IL1RB)

chemokine ligand 8

C-X-C motif

Interleukin 6

Interleukin 6

Interleukin 6

Interleukin 6

Interleukin 6

Interleukin 4

Protein

IL1R2 (CD121b,

TSG-1)

NAP1, SCYB8,

NAF, NAP-1,

MDNCF, MONAP,

LUCT, LYNAP,

8, IL8, K60, LECT,

GCP-1, GCP1, IL-

AMCF-I, b-ENAP,

CXCL8 (3-10C,

HSF, IFNB2, IL-6)

IL6 (BSF2, HGF,

HSF, IFNB2, IL-6)

IL6 (BSF2, HGF,

HSF, IFNB2, IL-6)

IL6 (BSF2, HGF,

HSF, IFNB2, IL-6)

IL6 (BSF2, HGF,

HSF, IFNB2, IL-6)

IL6 (BSF2, HGF,

4, MGC79402)

BCGF1, BSF1, IL-

IL4 (BCGF-1,

Alias(es)

Description,

generation

mark found in F2

in test subject;

Undernutrition

desaturation index"

with oxygen

increased

Diabetes

Metabolic

OSA/IHR

OSA

animals)

(CIH in

Sleep apnea

OSA

OSA

IHR

CIH

animals)

(CIH in

Sleep apnea

paper as

described in

promoter region

Hypomethylated

increased IL-8

IL-6 increased

Increased IL-6.

men with OSA

increased IL-6 in

miR-365

downregulation of

enrichment over IL6

Increased H3K9Ac

IL-4 increased

mark

Specific epigenetic

syndrome

insulin gene

methylation on

increased H3K20

IL1R2

apnea

Sleep

apnea

Sleep

apnea

Sleep

apnea

Sleep

apnea

Sleep

apnea

Sleep

apnea

Sleep

apnea

Sleep

condition

Associated

correlated

F2

tested

Gen.

(-114 CpG site) of

H3K20me

miR-365

increased

H3K9Ac

Histone

RNA or

negatively

protein expression;

"Increased IL1R2

increased

expression

Increased

increased

increased in men

inflammation

Inhibit

mark

Activating histone

expression

Increased

notes

(2015)

Hardikar et al

Chen et al (2016)

Gur et al (2016)

Lee et al (2017)

Gur et al (2016)

Gur et al (2016)

(2017)

Schaefer et al

(2017)

Cortese et al

Lee et al (2017)

original paper

2015)

(Hardikar et al.,

81

29

58

reference

review paper

(2017)

Park et al

(2019)

Chen et al

(2019)

Chen et al

(2019)

Chen et al

review paper
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Gene

KLF13

Kif20b

Keap1
associated protein 1

Description,

Protein

mark found in

RFLAT-1)

notes

adult offspring

pregnant subject;

Undernutrition of

Hypermethylation

inconsistent

adult offspring

mark found in

pregnant subject;

Undernutrition of

offspring

found in adult

test subject; mark

Overnutrition in

generation

mark found in F2

in test subject;

Undernutrition

notes

FKLF-2, NSLP1,

KLF13 (BTEB3,

MPP1)
Kruppel like factor 13

member 20B

KRMP1,

MPHOSPH1,

Kinesin family

KIF20B (CT90,

MGC9454)

MGC4407,

MGC20887,

MGC1114,

MGC10630,

KLHL19,

Kelch like ECH

KIAA0132,

Insulin receptor

Insulin receptor

insulin

Protein

KEAP1 (INrf2,

INSR (CD220)

INSR

IRF1

INSR (CD220)

IDDM2)

INS (IDDM1,

Alias(es)

Description,

INSR

INS

Gene

RNA or

increased

H3K4me

increased

H3K9me

Histone

RNA or

Gen.

F2

tested

Gen.

Associated

Diabetes

Diabetes

described in

syndrome

Metabolic

nephropathy

diabetic

retinopathy

diabetic

with high CRP

Diabetes

Pediatric OSA

apnea

syndrome

Metabolic

syndrome

Metabolic

syndrome

Metabolic

paper as

described in

Sleep

Diabetes

Diabetes

Diabetes

condition

Associated

Specific epigenetic

KLF13

methylation of

Decreased

Kif20b

Hypermethylation of

Keap1

methylation over

Increased H3K4

higher methylation

methylation of INSR

Increased

receptor methylation

increased insulin

insulin gene

methylation on

increased H3K9

mark

Specific epigenetic

original paper

Tobi et al (2014)

(2015)

Marumo et al

(2014)

Mishra et al

Kim et al (2012)

Tobi et al (2014)

et al (2010)

(2009) Plagemann

Plagemann et al

(2015)

Hardikar et al

original paper

review paper

2014)

(Tobi et al.,

69

85

2014)

(Tobi et al.,

al., 2010)

Plagemann et

et al., 2009;

(Plagemann

2015)

(Hardikar et al.,

reference

review paper

review paper

(2017)

Park et al

(2017)

Fodor et al

(2017)

Fodor et al

(2017)

Park et al

(2017)

Park et al

(2017)

Park et al

review paper
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MEG3

MCP-1

LXRa

Lrtm2

LEP

LEP

LEP

LEP

protein-1) or C-C
motif chemokine
ligand 2

MCP-1, MCP1,

MGC9434, SCYA2,

SMC-CF)

14q32.3.

on chromosome

(lncRNA) located

non-coding RNA

(MEG3) is a long

expressed gene 3

Maternally

chemoattractant

HC11, MCAF,

vitamin B-6

cytokine MCP-1

proinflamatory

the promoter of

Enrichment is at

offspring

member 3
(monocyte

found in adult

subfamily 1 group H

CCL2 (GDCF-2,

test subject; mark

Nuclear receptor

RLD-1)

Overnutrition in

mark

and transmembrane
domains 2

Repressive histone

Leucine rich repeats

increased in men

NR1H3 (LXR-a,

(OB, OBS)

weight control. LEP

balance and body

regulation of energy

Key player in the

Leptin

offspring

weight control. LEP

(OB, OBS)

found in adult

balance and body

Overnutrition in
test subject; mark

Leptin

(P0)

Low protein diet

regulation of energy

Key player in the

(OB, OBS)

weight control. LEP

balance and body

regulation of energy

Key player in the

Leptin

offspring

weight control. LEP

(OB, OBS)

found in adult

balance and body

Overnutrition in
test subject; mark

Leptin

regulation of energy

Key player in the

Alias(es)

increased

H3K4me

increased

H3K27me3

increased

H4K20me

Histone

F1

F1

tested

Diabetes

Diabetes

Diabetes

apnea

Sleep

apnea

Sleep

diabetes

Diabetes

diabetes

condition

syndrome

Metabolic

nephropathy

Diabetic

syndrome

Metabolic

CIH

OSA

syndrome

metabolic

resistance/

Insulin

syndrome

Metabolic

syndrome

metabolic

paper as

MEG3

methylation of

increased

MCP-1

methylation over

increased H3K4

LXRa

methylation of

increased

Lrtm2

tri-methylation over

increased H3K27

and leptin

6, insulin resistance,

increased hsCRP, IL-

leptin me reduced

methylation

promoter

reduced leptin

H4K20

methylation of leptin

increased

mark

(2016)

McCullough et al

Chen et al (2012)

Yu et al (2015)

(2017)

Cortese et al

Gur et al (2016)

(2013)

Khalyfa et al

(2011)

Jousse et al

(2015)

Masuyama et al

Hiramatsu (2012);

Masuyama and

al., 2016

McCullough et

60

2015)

(Yu et al.,

2013)

(Khalyfa et al.,

2011)

(Jousse et al.,

al., 2015)

Masuyama et

2012;

and Hiramatsu,

(Masuyama

reference

(2017)

Park et al

(2017)

Fodor et al

(2017)

Park et al

(2017)

Park et al

(2017)

Park et al

(2017)

Park et al

70

receptor tyrosine

NF-kappaB, NF-

NF-kB

B subunit 1

NFKB1 (KBF1,

NF-kB

B subunit 1

p50)

NFKB-p50, p105,

kB1, NFkappaB,

Nuclear factor kappa

NF-kappaB, NF-

metallopeptidase 9

Matrix

NFKB1 (KBF1,

p50)

NFKB-p50, p105,

kB1, NFkappaB,

Nuclear factor kappa

MMP9 (CLG4B)

MMP-9

metallopeptidase 9

Matrix

MMP9 (CLG4B)

remodeling and

High levels

fibrosis

Induce atrial

metallopeptidase 9

miR-146

miR-132

miR-21

decreased

metallopeptidase 9
Matrix

H3K9me2

Matrix

increased

MMP-9

MMP9 (CLG4B)

MMP-9

H3K9ac

Histone

RNA or

metallopeptidase 9

increased

offspring

found in adult

test subject; mark

Overnutrition in

notes

Matrix

MMP9 (CLG4B)

MMP9 (CLG4B)

MMP-9

factor

migration inhibitory

MMP-9

MIF (GIF, GLIF)

Macrophage

49 member 3

(FLJ22269,

LP2561, MFSD7)

Solute carrier family

SLC49A3

kinase

MET proto-oncogene,

HGFR, RCCP2)

Protein

MET (DFNB97,

Alias(es)

Description,

MIF

Mfsd7

Met

Gene

F1

tested

Gen.

Diabetes

Diabetes

apnea

Sleep

Diabetes

apnea

Sleep

Diabetes

Diabetes

apnea

Sleep

Diabetes

Diabetes

condition

Associated

retinopathy

diabetic

retinopathy

diabetic

OSA

retinopathy

diabetic

IHR

retinopathy

diabetic

retinopathy

diabetic

(Pediatric)

OSA

syndrome

Metabolic

nephropathy

diabetic

paper as

described in

Increased miR-146

Increased miR-132

increased MMP-9

MMP-9

Hypomethylation of

miR-21

upregulation of

MMP-9

H3K9me2 on

Decreased

on MMP-9

increased H3K9ac

inhibitory factor)

MIF (Macrophage

of Mfsd7

Reduced methylation

of Met

Hypomethylation

mark

Specific epigenetic

(2011)

Kovacs et al

(2011)

Kovacs et al

Volná et al (2011)

(2016)

Kowluru et al

al (2018)

(2018), Wang et

Zhang et al

(2013)

Zhong et al

(2013)

Zhong et al

2012

Khalyfa et al

et al (2016)

de Castro Barbosa

(2015)

Marumo et al

original paper

88

88

81

69,70

80

80

46

2016)

Barbosa et al.,

(de Castro

69

reference

review paper

(2017)

Fodor et al

(2017)

Fodor et al

(2017)

Fodor et al

(2019)

Chen et al

(2017)

Fodor et al

(2017)

Fodor et al

(2016)

Gur et al

(2017)

Park et al

(2017)

Fodor et al

review paper
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NRTK2

NPR2

Nos2

Nos2

NF-kB

NF-kB

NF-kB

Gene

B subunit 1

B subunit 1

NF-kappaB, NF-

2

2

iNOS, NOS,

NTRK2 (TRKB)

Increased
expression

tyrosine kinase 2

Sleepiness Scale

with Epworth

correlated

Diabetes

Diabetes

OSA/IHR

CIH

CIH

OSA

retinopathy

diabetic

retinopathy

diabetic

paper as

described in

promoter region

Hypomethylated

Nos2

enrichment over

Increased H3K9Ac

Nos2

tri-methylation over

increased H3K27

factor-kB

increased nuclear

Increased miR-21

Increased miR-155

mark

Specific epigenetic

(animal)

of NRTK2

increased expression

sites)

apnea

Sleep

apnea

Sleep

apnea

Sleep

apnea

Sleep

Diabetes

Diabetes

condition

Associated

negatively

tested

Gen.

(-608/-618 CpG

increased

H3K9Ac

increased

H3K27me3

miR-21

miR-155

Histone

RNA or

expressions;

and CNP protein

Increased NPR2

mark

Activating histone

mark

Repressive histone

neurotrophic receptor

receptor 2

ANPb, ANPRB,

GUCY2B, NPRB)

Natriuretic peptide

NPR2 (AMDM,

NOS2A)

Nitric oxide synthase

NOS2 (HEP-NOS,

NOS2A)

Nitric oxide synthase

iNOS, NOS,

it as NFκB.

p50)

NOS2 (HEP-NOS,

original article lists

NFKB-p50, p105,

typo, listing this

Review article has
as NFκ β, but the

B subunit 1

NF-kappaB, NF-

notes

kB1, NFkappaB,

Nuclear factor kappa

NFKB1 (KBF1,

p50)

NFKB-p50, p105,

kB1, NFkappaB,

Nuclear factor kappa

NFKB1 (KBF1,

p50)

NFKB-p50, p105,

kB1, NFkappaB,

Nuclear factor kappa

NF-kappaB, NF-

Protein

NFKB1 (KBF1,

Alias(es)

Description,

(2013)

Thomas et al

Chen et al (2016)

(2017)

Cortese et al

(2017)

Cortese et al

Ryan et al (2006)

(2011)

Kovacs et al

(2011)

Kovacs et al

original paper

81

10

88

88

reference

review paper

(2019)

Chen et al

(2016)

Gur et al

(2017)

Fodor et al

(2017)

Fodor et al

review paper
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p53

p300

Oxr1

Opn

Opn

Opn

Opn

Gene

Tumor protein p53

p300

p300)

TP53 (LFS1, p53)

E1A binding protein

EP300 (KAT3B,

Oxidation resistance 1

phosphoprotein 1

OXR1 (TLDC3)

Secreted

ETA-1, OPN)

phosphoprotein 1

SPP1 (BNSP, BSPI,

Secreted

ETA-1, OPN)

phosphoprotein 1

ETA-1, OPN)

SPP1 (BNSP, BSPI,

Secreted

phosphoprotein 1

SPP1 (BNSP, BSPI,

Secreted

ETA-1, OPN)

Protein

SPP1 (BNSP, BSPI,

Alias(es)

Description,

promoter

marks increased in

activating histone

promoter

marks increased in

activating histone

promoter

marks increased in

activating histone

promoter

increased in

histone marks

deactivating

notes

increased

H3K9ac

increased

H3K4me3

increased

H3K4me

decreased

H3K27me3

Histone

RNA or
tested

Gen.

Diabetes

Diabetes

Diabetes

Diabetes

Diabetes

Diabetes

Diabetes

condition

Associated

glucose; p300 siRNA

Increased
miRNA-34

diabetic
retinopathy

and ECM proteins.

vasoactive factors

overexpression of all

and glucose-induced

(except for VEGF)

prevented basal

increases with

of diabetes

p300 expression

Increased miR-200b

on OPN

Increased H3K9ac

across OPN

Increased H3K4me3

across OPN

Increased H3K4me1

OPN

H3K27me3 across

decreased

mark

Specific epigenetic

complications

macrovascular

retinopathy

diabetic

nephropathy

Diabetic

nephropathy

Diabetic

nephropathy

Diabetic

nephropathy

Diabetic

paper as

described in

(2011)

Kovacs et al

Chen et al (2010)

(2013)

Murray et al

Cai et al (2016)

Cai et al (2016)

Cai et al (2016)

Cai et al (2016)

original paper

88

89

61

61

61

61

reference

review paper

(2017)

Fodor et al

(2017)

Fodor et al

(2017)

Fodor et al

(2017)

Fodor et al

(2017)

Fodor et al

(2017)

Fodor et al

review paper
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PAI-1

PAI-1

PAI-1

PAI-1

PAI-1

PACT/RAX

Gene

ortholog; paper
records this as
PACT/RAX

inducible double
stranded RNA
dependent activator;

member 1; as PLAT

significantly
increased

member 1; as PLAT
inhibitor, it is required
for fibrinolysis down-

PAI1, PLANH1)

member 1; as PLAT

PAI1, PLANH1)

member 1; as PLAT

PAI1, PLANH1)

member 1; as PLAT

PAI1, PLANH1)

regulation

for fibrinolysis down-

inhibitor, it is required

Serpin family E

SERPINE1 (PAI,

regulation

for fibrinolysis down-

inhibitor, it is required

Serpin family E

SERPINE1 (PAI,

regulation

for fibrinolysis down-

inhibitor, it is required

Serpin family E

SERPINE1 (PAI,

regulation

w. genes

Serpin family E

SERPINE1 (PAI,

regulation

for fibrinolysis down-

inhibitor, it is required

Serpin family E

PAI1, PLANH1)

kinase (PKR)

inducible protein

mRNA associated

RAX is the murine

RAX is an interferon-

PACT is human,

kinase, interferon-

notes

Pact is a protein

Protein

SERPINE1 (PAI,

Alias(es)

Description,

decreased

H3K9me3

decreased

H3K9me2

increased

H3K9/14Ac

increased

H3K4me

decreased

H3K27me3

Histone

RNA or
tested

Gen.

Diabetes

Diabetes

Diabetes

Diabetes

Diabetes

Diabetes

condition

Associated

nephropathy

Diabetic

nephropathy

Diabetic

nephropathy

Diabetic

nephropathy

Diabetic

nephropathy

Diabetic

retinopathy

diabetic

paper as

described in

over PAI-1

decreased H3K9me3

over PAI-1

decreased H3K9me2

PAI-1

H3K9/14Ac on

Increased

over PAI-1

increased H3K4me

PAI-1

H3K27me3 over

decreased

Increased miR-29b

mark

Specific epigenetic

(2014)

Reddy et al

(2014)

Reddy et al

(2014)

Reddy et al

Sun et al (2010)

(2014)

Reddy et al

Silva et al (2011)

original paper

63

63

63

58

63

90

reference

review paper

(2017)

Fodor et al

(2017)

Fodor et al

(2017)

Fodor et al

(2017)

Fodor et al

(2017)

Fodor et al

(2017)

Fodor et al

review paper
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PPARγ

PPARγ

POSTN

POMC

proliferator activated
receptor gamma

PPARG1, PPARG2,

PPARgamma)

receptor gamma

PPARgamma)
Peroxisome

proliferator activated

PPARG1, PPARG2,

PPARG (NR1C3,

Peroxisome

PPARG (NR1C3,

periostin, PN)

Periostin

offspring

found in adult

test subject; mark

Overnutrition in

offspring

found in adult

test subject; mark

Overnutrition in

expression

Increased

offspring

found in adult

NPP, POC)

POSTN (OSF-2,

test subject; mark

Overnutrition in

offspring

CLIP, LPH, MSH,

POMC (ACTH,

Proopiomelanocortin

Overnutrition in

subunit

found in adult

Proopiomelanocortin

gamma, catalytic

POLGA)"

NPP, POC)

POMC (ACTH,

POMC

DNA polymerase

POLG (POLG1,

hypertrophy

test subject; mark

"

Polg1

Promote cardiac

epsilon

CLIP, LPH, MSH,

PRKCE

PPARGC1)

PKCε

deficiency

Methyl donor-

offspring

Protein kinase C

1 alpha

(PGC-1alpha,

PGC1, PGC1A,

PPARG coactivator

PPARGC1A

PGC1-α

test subject; mark
found in adult

Overnutrition in

regulator 2

notes

Period circadian

Protein

PER2 (KIAA0347)

Alias(es)

Description,

PER2

Gene

miR-31

Histone

RNA or

F1

F1

tested

Gen.

Diabetes

Diabetes

apnea

Sleep

Diabetes

Diabetes

apnea

Sleep

Diabetes

Diabetes

condition

Associated

syndrome

Metabolic

syndrome

Metabolic

animals)

(CIH in

Sleep apnea

syndrome

Metabolic

syndrome

Metabolic

Diabetes

IHR

syndrome

Metabolic

syndrome

Metabolic

paper as

described in

PPARγ

methylation of

increased

PPARγ

methylation of

increased

increased periostin

POMC

methylation of

increased

POMC

methylation of

Increased

diabetic retinopathy

miR-31

upregulation of

PGC1-α

methylation of (d21)

decreased

methylation in blood

increased PER2

mark

Specific epigenetic

Yu et al (2015)

Fujiki et al (2009)

Lee et al (2017)

et al (2010)

(2009) Plagemann

Plagemann et al

(2014)

Marco et al

of POLG1

Hypermethylation

Ren et al (2018)

Pooya et al (2012)

(2012)

Milagro et al

original paper

2015)

(Yu et al.,

2009

Fujiki et al.,

al., 2010)

Plagemann et

et al., 2009;

(Plagemann

2014)

(Marco et al.,

(2012)

Tewari et al

71

2012)

(Pooya et al.,

2012

(Milagro et al.,

reference

review paper

(2017)

Park et al

(2017)

Park et al

(2017)

Park et al

(2017)

Park et al

129

(2019)

Chen et al

(2017)

Park et al

(2017)

Park et al

review paper
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remodeling and

PI3K/AKT
fibrosis

Induce atrial

PTEN/

alpha 1

dysfunction

catalytic subunit

Attenuate

original article]

amended from

miR-21

apnea

Sleep

apnea

Sleep

IHR

IHR

miR-21

upregulation of

miR-630

downregulation of

Prdx4"

article read trdx4,

methylation of

of Prdx4 vs. controls

"reduced expression

[typo in review

miR-630

IH

[Prdx4], Gpx2)

apnea

Sleep

PRDX4

promoter regions of

Hypermethylated

mark

Specific epigenetic

increased DNA

PO

OSA/IHR

paper as

described in

Sod2, Cat, Txnrd2,

analyzed (Sod1,

– AOE genes were

the carotid body

chemoreflexes of

exaggerate

production,

increase ROS

AOE genes,

apnea

condition

Associated
Sleep

tested

Gen.

enzymes) Inhibit

Histone

RNA or

(anti-oxidant

notes

endothelial

AMP kinase

Peroxiredoxin 4

Peroxiredoxin 4

Protein

AMP-activated

Protein kinase

PRDX4 (AOE37-2)

Prdx4

PRKAA1

PRDX4 (AOE37-2)

Alias(es)

Description,

Prdx4

Gene

al (2018)

(2018), Wang et

Zhang et al

(2016)

Khalyfa et al

(2017)

Nanduri et al

et al (2012)

(2017), Nanduri

Nanduri et al

original paper

69,70

27

(19)

Nanduri et al.

49,82

reference

review paper

(2019)

Chen et al

(2019)

Chen et al

al (2018)

Perikleous et

(2019)

Chen et al

review paper
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RETN

RARB

RAGE

RAGE

RAGE

RAGE

Rab3a

FIZZ3, RETN1)

Resistin

beta

RETN (ADSF,

Retinoic acid receptor

NR1B2, RRB2)

MOK protein kinase

MOK protein kinase

MOK protein kinase

MOK protein kinase

growth and

resistance

Attenuate insulin

invasion

Increased tumor

RAS oncogene family

fibrosis.
RAB3A, member

RARB (HAP,

RAGE1, STK30)

MOK (RAGE,

RAGE1, STK30)

MOK (RAGE,

RAGE1, STK30)

MOK (RAGE,

RAGE1, STK30)

MOK (RAGE,

RAB3A

remodeling and

induce atrial

cell growth. May

proliferation and

metabolism, cell

as apoptosis,

processes such

multiple biological

the signaling of

pathway regulating

notes
an important

Protein

PI3K/AKT

Alias(es)

Description,

PTEN/

Gene

miR-452

decreased

H3K9me3

decreased

H3K9me2

increased

H3K9/14Ac

decreased

H3K27me3

miR21

Histone

RNA or
tested

Gen.

apnea

Sleep

Diabetes

Diabetes

Diabetes

Diabetes

Diabetes

apnea

Sleep

apnea

Sleep

condition

Associated

IHR

nephropathy

diabetic

nephropathy

Diabetic

nephropathy

Diabetic

nephropathy

Diabetic

nephropathy

Diabetic

OSA/IHR

IHR

paper as

described in

miR-452

downregulation of

RARB

Hypermethylation of

RAGE

H3K9me3 over

decreased

over RAGE

decreased H3K9me2

RAGE

H3K9/14Ac on

Increased

RAGE

H3K27me3 over

decreased

RAB3a

promoter regions of

Hypermethylated

pathway

which targets this

up-regulated mir21

mark

Specific epigenetic

(2019)

Uchiyama et al

Ko et al (2013)

(2014)

Reddy et al

(2014)

Reddy et al

(2014)

Reddy et al

(2014)

Reddy et al

(2015)

Cortese et al

al (2018)

(2018), Wang et

Zhang et al

original paper

73

67

63

63

63

63

84

69,70

reference

review paper

(2019)

Chen et al

(2017)

Fodor et al

(2017)

Fodor et al

(2017)

Fodor et al

(2017)

Fodor et al

(2017)

Fodor et al

(2019)

Chen et al

(2019)

Chen et al

review paper
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linker 1

Slco1a1

Mus musculus
(house mouse)
gene

anion transporter
family, member 1a1

offspring
solute carrier organic

MDU1, NACAE)

test subject; mark

Overnutrition in
found in adult

member 2

4F2HC, 4T2HC,

CD98, CD98HC,

Solute carrier family 3

SLC3A2 (4F2,

increased

Slc3a2

H3K9me3

miR-23b-3p

miR-195

miR-203

miR-218

Histone

RNA or

member 4

SaO2

AHI and minimum

correlated with

negatively

oxide synthase;

endothelial nitric

Repress

for deacetylation

Sirt1 targets Foxo4

resistance

Potentiate insulin

apoptosis

Potentiate

adult offspring

mark found in

pregnant subject;

Undernutrition of

notes

Solute carrier family 2

Sirtuin 1

Sirtuin 1

Sirtuin 1

SLC2A4 (GLUT4)

HDAC;(SIR2L1)

SIRT1 A Class III

HDAC;(SIR2L1)

SIRT1 A Class III

HDAC;(SIR2L1)

SIRT1 A Class III

Slc2a4

SIRT1

SIRT1

SIRT1

HDAC;(SIR2L1)

Sirtuin 1

SIRT1 A Class III

SIRT1

transcription factor 3

CBFA3, PEBP2A3)
Selenoprotein P

Runt related

receptor 1

FLJ21882, SAX3)

RUNX3 (AML2,

Roundabout guidance

ROBO1 (DUTT1,

Raftlin)

Raftlin, lipid raft

KIAA0084, MIG2,

Protein

RFTN1 (FLJ23866,

Alias(es)

Description,

SELENOP

RUNX3

Robo1

RFTN1

Gene

F1

tested

Gen.

Diabetes

Diabetes

Diabetes

apnea

Sleep

Diabetes

Diabetes

Diabetes

apnea

Sleep

Diabetes

apnea

Sleep

Diabetes

condition

Associated

nephropathy

diabetic

syndrome

Metabolic

Diabetes

IHR

Diabetes

retinopathy

diabetic

retinopathy

diabetic

IHR

nephropathy

diabetic

IHR

syndrome

Metabolic

paper as

described in

Slco1a1

Hypermethylation of

Slc3a2

methylation of

Increased

H3K9 on Slc2a4

methylation of

increased tri-

SIRT1

Down-regulated

of SIRT1

reduced expression

3p and miR-195

Increased miR-23b-

3p and miR-195

Increased miR-23b-

miR-203

downregulation of

RUNX3

Hypomethylationof

miR-218

upregulation of

RFTN1

methylation of

Decreased

mark

Specific epigenetic

(2015)

Marumo et al

et al (2016)

de Castro Barbosa

(2019)

Yonamine et al

(2015)

and Chen et al

Lin et al (2018)

(2011)

Chuang et al

(2016)

Mortuza et al

(2016)

Mortuza et al

(2019)

Uchiyama et al

Ko et al (2013)

Liu et al (2017)

Tobi et al (2014)

original paper

69

2016)

Barbosa et al.,

(de Castro

55,56

87,92

87,92

74

67

65

2014)

(Tobi et al.,

reference

review paper

(2017)

Fodor et al

(2017)

Park et al

(2019)

Chen et al

(2017)

Fodor et al

(2017)

Fodor et al

(2019)

Chen et al

(2017)

Fodor et al

(2019)

Chen et al

(2017)

Park et al

review paper
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member 3

member 6

(HsT17432,

SOD2

Sod2

H3K9Ac
increased

2

Diabetes

Diabetes

diabetic

IH

OSA/IHR

syndrome

Metabolic

nephropathy

diabetic

IHR

paper as

described in

"

promoter regions

Hypermethylated

SMAD7

methylation of

Increased

SMAD6

Hypermethylation of

miR-145

downregulation of

mark

Specific epigenetic

retinopathy

diabetic

retinopathy

on Sod2

Increased H3K9ac

across Sod2

decreased H3K4

Sod1"

methylation of

increased DNA

of Sod1

reduced expression

apnea

Sleep

apnea

Sleep

Diabetes

Diabetes

apnea

Sleep

condition

Associated

Txnrd4, Gpx2)

PO

tested

Gen.

AM displayed

H3K4 decreased

miR-145

Histone

RNA or

Sod2, Cat, Txnrd2,

analyzed (Sod1,

AOE genes were

the carotid body

chemoreflexes of

exaggerate

production,

increase ROS

AOE genes,

enzymes) Inhibit

(anti-oxidant

adult offspring

mark found in

pregnant subject;

Undernutrition of

sprouting

sympathetic nerve

remodeling and

Attenuate aortic

notes

Superoxide dismutase

2

Superoxide dismutase

1

IPOA)

SOD2

Superoxide dismutase

1

SOD1 (ALS, ALS1,

Superoxide dismutase

IPOA)

member 7

MADH8)

SOD1 (ALS, ALS1,

SMAD family

SMAD7 (MADH7,

MADH6, MADH7)

SMAD family

SMAD6

2, MADH3)

SMAD family

(HsT17436, JV15-

Protein

SMAD3

Alias(es)

Description,

Sod2

Sod1

Sod1

SMAD7

SMAD6

Smad3

Gene

(2007)

(2011), He et al

Zhong et al

(2007)

(2011), He et al

Zhong et al

(2017)

Nanduri et al

et al (2012)

(2017), Nanduri

Nanduri et al

Tobi et al (2014)

Ko et al (2013)

Yu et al (2017)

original paper

78,79

78,79

(19)

Nanduri et al.

49,82

2014)

(Tobi et al.,

67

76

reference

review paper

(2017)

Fodor et al

(2017)

Fodor et al

al (2018)

Perikleous et

(2019)

Chen et al

(2017)

Park et al

(2017)

Fodor et al

(2019)

Chen et al

review paper
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SOD2

Sod2

SOD2

SOD2

Sod2

Sod2

SOD2

Alias(es)

Description,

Sod2

Gene

enzymes) Inhibit

IH

of Sod 2 vs. controls

Txnrd4, Gpx2)

Sod2"

methylation of

increased DNA

reduced expression

analyzed (Sod1,

2
Sod2, Cat, Txnrd2,

– AOE genes were

Superoxide dismutase

genes"

Sod2 and Duox2

CpG islands in rat

of

"

rats exposed to IH"

apnea

AM, respectively, in

Analysis of DNA
methylation status

12-fold in CB and

analyzed –

DNA methylation

"

incremented 6- and

Sleep

IH

of Sod2

promoter regions

Hypermethylated

H4K20me3 on Sod 2

Increased

mark

Specific epigenetic

proteins were

apnea

Sleep

OSA/IHR

retinopathy

diabetic

paper as

described in

corresponding

PO

F1

apnea

Sleep

Diabetes

condition

Associated

of Sod2 gene

levels in AM

2

tested

Gen.

and CB and

"– DNMT mRNA

Superoxide dismutase

the carotid body

chemoreflexes of

exaggerate

production,

increase ROS

AOE genes,

(anti-oxidant

2

increased

Superoxide dismutase

H4K20me3

Histone

RNA or

2

notes

Superoxide dismutase

Protein

(2017)

Nanduri et al

(2012)

Nanduri et al

et al (2012)

(2017), Nanduri

Nanduri et al

(2007)

(2011), He et al

Zhong et al

original paper

(19)

Nanduri et al.

(18)

Nanduri et al.

49,82

78,79

reference

review paper

al (2018)

Perikleous et

al (2018)

Perikleous et

(2019)

Chen et al

(2017)

Fodor et al

review paper

Spry1

Spry1

Spry0

SP140

Gene

TGF-β1

TGF-β1

TGF-β1

Tbrg4

sRAGE

80

Induce atrial
remodeling and
fibrosis

RTK signaling

Sleepiness Scale

with Epworth

factor beta 1

DPD1, TGFB,

factor beta 1

DPD1, TGFB,

TGFbeta)

Transforming growth

TGFB1 (CED,

TGFbeta)

Transforming growth

TGFB1 (CED,

TGFbeta)

factor beta 1

DPD1, TGFB,

offspring

Transforming growth

TGFB1 (CED,

KIAA0948)

test subject; mark

Overnutrition in
found in adult

factor beta regulator 4

FASTKD4,

inflammation

H_TD2522F11.8,

Transforming growth

receptor for AGEs

(sRAGE)
and may prevent

acts as a decoy

Soluble RAGE

miR-200c

miR-200b

miR-192

miR-21

miR 29c

F1

Diabetes

Diabetes

Diabetes

Diabetes

apnea

Sleep

apnea

Sleep

Diabetes

Diabetes

diabetic

OSA/IHR

paper as

described in

promoter region

Hypermethylated

mark

Specific epigenetic

nephropathy

diabetic

nephropathy

diabetic

nephropathy

diabetic

syndrome

Metabolic

OSA

IHR

nephropathy

diabetic

nephropathy

Increased miR-200c

Increased miR-200b

Increased miR-192

of Tbrg4

Reduced methylation

sRAGE

Low levels of

miR-21

upregulation of

Increased miR-29c

Increased miR-29c

SP140

apnea

Sleep

condition

Associated

correlated

homolog 1; Sprouty

antagonist 1

tested

Gen.

(-194 CpG site) of

miR 29c

Histone

RNA or

positively

protein expression;

Decreased SP140

notes

protein sprouty

antagonist 1

RTK signaling

homolog 1; Sprouty

protein sprouty

signaling antagonist 0

TBRG4 (Cpr2,

SPRY1 (hSPRY1)

SPRY1 (hSPRY1)

SPRY1 (hSPRY1)

Sprouty RTK

protein

LYSP100-B)

SP140 nuclear body

(LYSP100-A,

Protein

SP140

Alias(es)

Description,

Kato et al (2007)

Kato et al (2011),

Kato et al (2007)

Kato et al (2011),

Kato et al (2007)

Kato et al (2011),

et al (2016)

de Castro Barbosa

Volná et al (2011)

al (2018)

(2018), Wang et

Zhang et al

Long et al (2011)

Long et al (2011)

Chen et al (2016)

original paper

70,71

70,71

70,71

2016)

Barbosa et al.,

(de Castro

69,70

73

73

81

reference

review paper

(2017)

Fodor et al

(2017)

Fodor et al

(2017)

Fodor et al

(2017)

Park et al

(2019)

Chen et al

(2017)

Fodor et al

(2017)

Fodor et al

(2019)

Chen et al

review paper

81

TSPAN17

TSP-1

TNF-α

TNF-α

invasion.

migration and

proliferation,

and decreased

promoted apoptosis

TSPAN17,

expression of

decreased the

of miR‑378a‑3p

Overexpression

TSPAN17.

including

multiple targets,

378a-3p

Up-regulated miR-

Guo et al (2019)

Delic et al (2016)

Gur et al (2016)

60

75

table 3

73

27

reference

review paper

(2019) and

Chen et al

(2017)

Fodor et al

(2019)

Khurana et al

(2019)

Chen et al

(2019)

Chen et al

review paper

(2015)

IHR

Increased miR-320c

TNF-α, and IL-8

nuclear factor-k β,

TNF-α

increased level of

(2019)

Uchiyama et al

(2016)

Khalyfa et al

original paper

Torre et al

apnea

Sleep

nephropathy

diabetic

OSA

OSA

miR-452

downregulation of

miR-630

downregulation of

mark

Specific epigenetic

to CPAP treatment;

PO

Diabetes

apnea

Sleep

apnea

Sleep

IHR

IHR

paper as

described in

pressure decreases

miR-378a-3p

miR-320c

P0

apnea

Sleep

apnea

Sleep

condition

Associated

TM4SF17)

miR-378a-3p

increased

summary of table 3

tested

Gen.

Predicts blood

Tetraspanin 17

Thrombospondin 1

Tumor necrosis factor

Tumor necrosis factor

miR-452

miR-630

Histone

RNA or

(FBX23, FBXO23,

TSPAN17

1, TSP1)

THBS-1, TSP, TSP-

THBS1 (THBS,

TNFSF2)

alpha, TNFA,

TNF (DIF, TNF-

TNFSF2)

alpha, TNFA,

TNF (DIF, TNF-

TNFSF2)

resistance

Attenuate insulin

TNF-α

Tumor necrosis factor

dysfunction

pathways

alpha, TNFA,

endothelial

notes
Attenuate

TNF (DIF, TNF-

Protein

junction

Alias(es)

Description,

tight

Gene

82

VEGF

VEGF

VEGF

VEGF

VEGF

VEGF

Txnrd2

Txnrd2

TXNIP

Gene

interacting protein

Vascular endothelial
growth factor A

VEGF-A, VPF)

growth factor A

VEGFA (VEGF,

Vascular endothelial

VEGF-A, VPF)

growth factor A

VEGF-A, VPF)

VEGFA (VEGF,

Vascular endothelial

growth factor A

VEGF-A, VPF)

VEGFA (VEGF,

Vascular endothelial

growth factor A

VEGF-A, VPF)

VEGFA (VEGF,

Vascular endothelial

growth factor A

VEGFA (VEGF,

Vascular endothelial

VEGF-A, VPF)

2

TR3, TRXR2)

VEGFA (VEGF,

Thioredoxin reductase

2

TR3, TRXR2)

TXNRD2 (TR,

Thioredoxin reductase

TXNRD2 (TR,

VDUP1)

HHCPA78, THIF,

Thioredoxin

EST01027,

Protein

TXNIP (ARRDC6,

Alias(es)

Description,

original article]

amended from

article read trdx4,

[typo in review

miR17–5p

miR-31

miR-21

miR-20a

miR-18a

Diabetes

Diabetes

Diabetes

Diabetes

Diabetes

Diabetes

diabetic

IH

OSA/IHR

nephropathy

diabetic

paper as

described in

of Txnrd2; increased

reduced expression

TXNRD2

promoter regions of

Hypermethylated

TXNIP

of the promoter of

Hypomethylation

mark

Specific epigenetic

retinopathy

diabetic

retinopathy

diabetic

retinopathy

diabetic

retinopathy

diabetic

retinopathy

diabetic

retinopathy

Increased miR17–5p

Increased miR-31

Increased miR-21

Increased miR-20a

Increased miR-18a

Increased miR-133

Txnrd2

apnea

Sleep

apnea

Sleep

Diabetes

condition

Associated

[Prdx4], Gpx2)

PO

tested

Gen.

DNA methylation of

miR-133

Histone

RNA or

Sod2, Cat, Txnrd2,

analyzed (Sod1,

– AOE genes were

the carotid body

chemoreflexes of

exaggerate

production,

increase ROS

AOE genes,

enzymes) Inhibit

(anti-oxidant

of the promoter

Hypomethylation

notes

(2011)

Kovacs et al

(2011)

Kovacs et al

(2011)

Kovacs et al

(2011)

Kovacs et al

(2011)

Kovacs et al

(2011)

Kovacs et al

(2017)

Nanduri et al

et al (2012)

(2017), Nanduri

Nanduri et al

Chen et al (2016)

Shah et al (2015),

original paper

88

88

88

88

88

88

(19)

Nanduri et al.

49,82

65,66

reference

review paper

(2017)

Fodor et al

(2017)

Fodor et al

(2017)

Fodor et al

(2017)

Fodor et al

(2017)

Fodor et al

(2017)

Fodor et al

al (2018)

Perikleous et

(2019)

Chen et al

(2017)

Fodor et al

review paper
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(human cartilage
glycoprotein)

WNT1 (INT1)

CHI3L1 (GP39,

YKL40)

Wnt1

YKL-40
Chitinase 3 like 1

Wnt family member 1

Wnt family member 1

WNT1 (INT1)

Wnt1

Wnt family member 1

Protein

WNT1 (INT1)

Alias(es)

Description,

Wnt1

Gene

to CPAP treatment

pressure decreases

Predicts blood

miR-100-5p

increased

offspring

found in adult

test subject; mark

Overnutrition in

offspring

Diabetes
Diabetes
Diabetes

miR-122
miR-124
miR-126

apnea

Sleep

mir-107

apnea

Sleep

Diabetes

apnea

Sleep

Diabetes

Diabetes

Diabetes

condition

Associated

Diabetes

(D7)

F1

F1

tested

Gen.

miR-107

miR-100-5p

Let-7e

H4Ac reduced

increased

found in adult

H3K9me

test subject; mark

H3Ac reduced

Histone

RNA or

Overnutrition in

offspring

found in adult

test subject; mark

Overnutrition in

notes

Diabetes

Diabetes

Diabetes

IHR

Diabetes

IHR

Diabetes

OSA

syndrome

metabolic

syndrome

Metabolic

syndrome

Metabolic

paper as

described in

miR-107

Downregulation of

100-5p

Up-regulated miR-

increased

glycoprotein)

cartilage

YKL-40 (human

Wnt1 H4Ac reduced

H3K9 over Wnt1

methylation of

Increased

acetylation of H3

Decreased

mark

Specific epigenetic

Li et al (2017)

Torre et al (2015)

Sanchez-de-la-

Gur et al (2016)

(2012)b

a, Yang et al

Yang et al (2012)

(2012)b

a, Yang et al

Yang et al (2012)

Yang et al (2012)

original paper

63

60

2012a,b)

(Yang et al.,

2012a,b)

(Yang et al.,

2012a,b)

(Yang et al.,

reference

review paper

(2019)

Khurana et al

(2019)

Khurana et al

(2019)

Khurana et al

(2019)

Chen et al

(2019)

Khurana et al

(2019)

Chen et al

(2019)

Khurana et al

(2017)

Park et al

(2017)

Park et al

(2017)

Park et al

review paper

84

Gene

Alias(es)

Description,

Protein

hypertension

pulmonary

Attenuate

dysfunction

Attenuate cognitive

notes

Diabetes
Diabetes
Diabetes
Diabetes
Diabetes
Diabetes
Diabetes
Diabetes
Sleep

miR-143
miR-145
miR-146a
miR-15a
miR-17-5p
miR-181a
miR-187
miR-195
miR-199-3p

apnea

Sleep

Diabetes

miR-223
miR-223

Diabetes

apnea

Sleep

miR-21

miR-207

Diabetes

miR-134

apnea

Diabetes

miR-133

condition

Associated
Diabetes

tested

Gen.

miR-132

Histone

RNA or

miR-223

downregulation of

223

obesity
OSA/IHR

low levels of miR-

miR-207

downregulation of

miR-199-3p

Downregulation of

Hao et al (2019)

Wen et al (2015)

Gao et al (2017)

68

Wen et al 2015

66

(2019)

Chen et al

(2019)

Khurana et al

(2019)

Khurana et al

(2019)

Chen et al

(2019)

Chen et al

(2019)

Khurana et al

(2019)

Khurana et al

(2019)

Khurana et al

(2019)

Khurana et al

(2019)

Khurana et al

(2019)

Khurana et al

(2019)

Khurana et al

(2019)

(2019)

Khurana et al

(2019)

Khurana et al

(2019)

Khurana et al

review paper

Khurana et al

63

reference

review paper

143

Li et al (2017)

original paper

low levels of miR-

mark

Specific epigenetic

Diabetes and

Diabetes

IHR

IHR

Diabetes

Diabetes

Diabetes

Diabetes

Diabetes

Diabetes

Diabetes

Diabetes

Diabetes

Diabetes

Diabetes

paper as

described in

85

Gene

Alias(es)

Description,

Protein

to CPAP treatment

pressure decreases

Predicts blood

miR-486-5p

to CPAP treatment

pressure decreases

Predict blood

dysfunction

Promote cognitive

notes

Diabetes
Diabetes
Diabetes
Diabetes
Diabetes
Diabetes
Sleep

miR-320
miR-335
miR-33a/b
miR-34a
miR-375
miR-376
miR-485-5p

miR-486-5p

miR-486-5p

Diabetes

miR-30d

apnea

Sleep

apnea

Sleep

apnea

Diabetes

miR-29

apnea

Sleep

Diabetes

condition

Associated

Diabetes

tested

Gen.

miR-27b

miR-26b

miR-26b

Histone

RNA or

IHR

IHR

IHR

Diabetes

Diabetes

Diabetes

miR-486-5p

downregulation of

Down-regulated

miR-485-5p

Downregulation of

335

obesity
Diabetes

low levels of miR-

miR-26b

upregulation of

mark

Specific epigenetic

Diabetes and

Diabetes

Diabetes

Diabetes

Diabetes

IHR

Diabetes

paper as

described in

Torre et al (2015)

Sanchez-de-la-

Torre et al (2015)

Sanchez-de-la-

Li et al (2017)

Gao et al (2017)

original paper

60

60

63

66

reference

review paper

(2019)

Chen et al

(2019)

Chen et al

(2019)

Chen et al

(2019)

Khurana et al

(2019)

Khurana et al

(2019)

Khurana et al

(2019)

Khurana et al

(2019)

Khurana et al

(2019)

Khurana et al

(2019)

Khurana et al

(2019)

Khurana et al

(2019)

Khurana et al

(2019)

Chen et al

(2019)

Khurana et al

review paper
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Gene

Alias(es)

Description,

Protein

F1

global

of miRNA let-7c

Increased expression

offspring

in liver

syndrome

Metabolic

miR-486-5p

downregulation of

miR-664a

Down regulation of

574-5p

upregulation of miR-

mark

Specific epigenetic

found in adult

Diabetes

Diabetes

IHR

Diabetes

Diabetes

Diabetes

Diabetes

IHR

IHR

Diabetes

Diabetes

paper as

described in

hypermethylation

miRNA Let- 7c

apnea

Sleep

Diabetes

miR-96
miR485-5p

Diabetes

Diabetes

miR-9
miR-93

Diabetes

apnea

Sleep

miR-7

miR-664a

Sleep

miR-574-5p
apnea

Diabetes

miR-543

condition

Associated
Diabetes

tested

Gen.

miR-503

Histone

RNA or

test subject; mark

Overnutrition in

offspring

found in adult

test subject; mark

Overnutrition in

treatment

decreases to CPAP

blood pressure

MiR Predicts

AHI

correlated with

negatively

atherosclerosis;

A marker of

notes

Yu et al (2015)

et al (2016)

de Castro Barbosa

Li et al (2017)

Li et al (2018)

Li et al (2017)

original paper

2015)

(Yu et al.,

2016)

Barbosa et al.,

(de Castro

63

61

63

reference

review paper

(2017)

Park et al

(2017)
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